

NATIONAL TUBERCULOSIS, LEPROSY AND LUNG DISEASE PROGRAM

INTEGRATED CURRICULUM PARTICIPANTS MANUAL



September 2017 Edition





Integrated Curriculum Participants Manual

© September 2017

National Tuberculosis, Leprosy and Lung Disease Program (NTLD-Program)

This curriculum was developed and published in the Kenyan context and is rolled out through the Ministry of Health.



Foreword

Tuberculosis remains a major cause of morbidity and mortality in Kenya. It affects all age groups, but has its greatest toll in the most productive age group of 15 to 44 years. The major factor responsible for the TB disease burden in Kenya is the concurrent HIV epidemic. To address challenges posed by the tuberculosis epidemic in the era of HIV, the Ministry of Health through The National Tuberculosis, Leprosy and Lung Disease Program (NTLD-Program) has identified areas for increased support which include sustained public health education campaigns to promote early care seeking and adherence to treatment at community level, and health care worker training and support for better TB case management.

This guideline is a revision of the earlier version produced in 2013 and has integrated all the different thematic areas in an easy to read version. The immediate short-term goal is to increase the detection of TB cases and sustain the successful treatment of those diagnosed. All these efforts are designed in a bid to achieve the end TB strategy goal of ending the global tuberculosis epidemic.

This guideline highlights key elements of lung disease to aid in its basic diagnosis and management. The incidence of respiratory diseases has continued to rise due to a rapid increase in a number of risk factors such as tobacco smoking habits in developing countries. Kenya in an effort to improve the health of its population is strengthening the management of lung diseases through a number of approaches, key among them the Practical Approach to Lung Health (PAL) which entails use of standardized regimens, equipping and stocking facilities with necessary medicines and strengthening of community structures.

This guideline should therefore be used as the technical reference material by all health care workers involved in TB, Leprosy and Lung Disease care and can also be used for training of health care workers in conjunction with other training materials.

It is my sincere hope that all healthcare workers will find the integrated manual useful for successful implementation of tuberculosis, Leprosy and lung disease control activities.



Acknowledgements

The Ministry of Health and the National Tuberculosis, Leprosy and Lung Disease Program (NTLD-Program) are indebted to many individuals and organizations whose support and collaboration have made possible the updating of this edition of the national guidelines for the treatment and prevention of Tuberculosis for health workers.

We are grateful to the Global Fund and USAID through TB ARC for providing financial and technical support to enable development of the guidelines. Other partners that collaborated include CDC, KAPTLD, NASCOP, AMPATH, University of Nairobi, Counties, WHO, CHS, MSF, HSO, Stop TB Partnership, PATH, MSH, KNH organizations whose staff put in much effort to ensure the success of this process. Special thanks goes to the NTLD-P staff who worked tirelessly in coordination and development of this guideline.

It is our sincere hope that the guidelines will be useful in improving awareness about TB control in Kenya in an effort to find missing cases.



Acronyms

A&C	Advocacy and Communication	
AM	Amikacin	
ARI	Acute Respiratory Infections	
CHC	Community Health Committee	
CHV	Community Health Volunteers	
CM	Capreomycin	
COPD	Obstructive Pulmonary Disease	
CPT	Cotrimoxazole Preventive Therapy	
Cs	Cycloserine	
CXT	Cotrimoxazole	
DM	Diabetes Mellitus	
DOT	Directly Observed Therapy	
DR-TB	Drug Resistant TB	
DST	Drug Susceptibility Testing	
E	Ethambutol	
EPTB	Extra Pulmonary TB	
Eto	Ethionamide	
F	Female	
FBF	Fortified Blended Flours	
FDC	Fixed Dose Combinations	
FFT	After failure of First Line Treatment	
FRT	After failure of Retreatment	
GERD	Gastroesophangeal Reflux	
Gfx	Gatifloxacin	
Н	Isoniazid	
HCWs	Health Care Workers	

HIV	Human Immunodeficiency Virus
IDF	International Diabetes Federation
IGRA	Interferon Gamma Release Assay
ILDS	Interstitial Lung diseases
IPC	Infection Prevention and Control
IPT	Isoniazid Preventive Therapy
IYCN	Infant and Young Child Nutrition
Km	Kanamycin
LFX	Levofloxacin
LTBI	Latent TB Infection
М	Male
MAC	M. avium Complex
MDR TB	Multidrug Resistance
Mfx	Moxifloxacin
MTB	Mycobacterium tuberculosis
Ν	New
NACS	Nutrition Assessment Counselling and Support
NSA	Non State Actors
NSP	National Strategic Plan
NTLD-P	National Tuberculosis, Leprosy and Lung Disease Program
NTM	Non-tuberculous Mycobacteria
Ofx	Ofloxacin
PACS	Primary Care Asthma Control Screening Tool
PAL	Practical Approach to Lung Health
PAS	P-aminosalicylic acid

PCR Polymerase Chain Reaction

	PDR TB	Polydrug Resistance
	PET	Positron Emission Tomography
	PLHIV	People Living With HIV
	PTB	Pulmonary TB
	Pto	Prothionamide
	R	Relapse
	R	Rifampicin
	RDU	Definition of Rational Drug Use
	RR TB	Rifampicin Resistance
	RUSF	Ready to Use Supplementary Foods
	RUTF	Ready to Use Therapeutic Food
	S	Streptomycin
	SCHMT	sub-County Health Management Team
	SHS	Second Hand Smoke
	SLE	Systemic Lupus Erythematosis
	ТВ	Tuberculosis
	TI	Transfer in
	Trd	Terizidone
	TSR	Treatment Success Rate
I	TST	Tuberculin Skin Test
	TWG	Technical Working Group
	WHO	World Health Organization
	XDR TB	Extensive Drug Resistance
	Ζ	Pyrazinamide



Contents

FOREWORD	
ACKNOWLEDGEMENT	
LIST OF ABBREVIATIONS	
TABLE OF CONTENTS	IV
MODULE 1: INTRODUCTION	1
MODULE 2: LUNG DISEASES	
TOPIC 1: Introduction	
TOPIC 2: Pneumonia	
TOPIC 3: Asthma	
TOPIC 4: COPD	
MODULE 3: TUBERCULOSIS	
TOPIC 1: Background and Introduction to Tuberculosis	
TOPIC 2: Diagnosis and treatment of Tuberculosis	
TOPIC 3: TB/HIV Co-Infection	
TOPIC 4: Tuberculosis in Children	
TOPIC 5: TB and Diabetes	
TOPIC 6: TB in Special Populations	
TOPIC 7: Drug Resistant TB	
MODULE 4: LEPROSY	
TOPIC 1: Background and Introduction	
TOPIC 2: Diagnosis and treatment of Leprosy	
MODULE 5: LABORATORY DIAGNOSIS OF TB AND LEPROSY	
TOPIC 1: Introduction	
MODULE 6: NUTRITION ASSESSMENT COUNSELLING AND SUPPORT	147
TOPIC 1: Objectives of nutrition in Tuberculosis, leprosy and lung disease	145
TOPIC 2: Relationship between Nutrition Lung Diseases and Leprosy	145
TOPIC 3: Nutrition Assessment Counselling and Support	145
TOPIC 4: Making a Nutrition Diagnosis	
TOPIC 5: Nutrition Interventions	

Ø



MODULE 7: NTLD-P COMMODITIES SUPPLY CHAIN MANAGEMENT PHARMACEUTICAL MANAGEMENT	
TOPIC 1: The Pharmaceutical Management Cycle	
TOPIC 2: Quantification of Anti-Tuberculosis Medicines	
TOPIC 3: Good inventory management	
TOPIC 4: Pharmacovigilance	
MODULE 8: ENGAGING COMMUNITIES, PATIENTS AND NON STATE ACTORS (NSA) IN TB, LEPROSY AND LUNG HEALTH CARE SERVICES	
TOPIC 1: Background	
TOPIC 2: Prevention	
TOPIC 3: Diagnosis	
TOPIC 4: Advocacy	
TOPIC 5: ENGAGE-TB Approach	
TOPIC 6: TB Infection, Prevention, and Control at the Community Level	
TOPIC 7: Social Determinants of Health	219
MODULE 9: ADVOCACY AND COMMUNICATION	220
TOPIC 1: Introduction	220
TOPIC 2: Advocacy	
TOPIC 3: Communication	
MODULE 10: MONITORING AND EVALUATION	220
TOPIC 1: Introduction	
TOPIC 2: Standard Reports	
TOPIC 3: data Quality Assurance Mechanisms	
TOPIC 4: Operations Research	
MODULE 11: SOCIAL PROTECTION, POVERTY ALLEVIATION AND ACTIONS ON OTHER DETERMINANTS OF TUBERCULOSIS	255
TOPIC 1: Background	
TOPIC 2: TB and Poverty	
TOPIC 3: Overcoming Barriers to TB Treatment	

₩ ₩

V

Five Day Integrated Lung Health Training Schedule

	Day 1	
Time	Торіс	Facilitator
8.00 – 9.00 am	Introduction/Norms	Coordinator
	Opening remarks	County Director-Health
	Pre-test	Coordinator
	Objectives of the training	MO/CO/Nurse
9.00 - 9.30 am	Pneumonia	MO/CO/Nurse
9:30 - 10.15 am	Asthma	MO/CO/Nurse
10.15 – 11.00 am	COPD	MO/CO/Nurse
11.00- 11.20 am	TEA BREAK	
11.20 - 11.50 am	Other Respiratory diseases	MO/CO/Nurse
11.50 am - 1.00 pm	Practices	MO/CO/Nurse
1.00 - 2.00pm		
2.00 - 2.30 pm	Introduction and Epidemiology of TB	MO/CO/Nurse
2.20 - 2.50 pm	Active Case finding	MO/CO/Nurse
3.00 - 5.00 pm	Lab Diagnosis of TB	Lab Technologist
5.00 – 5.20 pm	Tea Break	



	Day 2	
Time	Торіс	Facilitator
8.00 - 8.20 Am	Recap	Nutritionist
8.20 - 10.00 Am	Treatment of TB	MO/CO/Nurse
10.00 -10.30 Am	Non-tuberculosis Mycobacterium (NTM)	MO/CO/Nurse
10.30 - 10.50 Am		
10.50 - 1.00 Pm	TB and HIV	MO/CO/Nurse
1.00 - 2.00 Pm	Lunch Break	
2.00 – 3.30 Pm	TB in children	MO/CO/Nurse
3.30 - 4.30 Pm	TB in special populations	MO/CO/Nurse
4.30 - 5.00 Pm	Pharmacovigilance	Pharmacist
5.00Pm - 5.20Pm		Lab Technologist
5.20- 6.00 Pm	Plenary	Lab Technologist

	Day 3	
Time	Торіс	Facilitator
8.00 - 8.20 AM	Recap	Pharmacist
8.20 - 10.30 AM	Drug Resistant (DR-TB)	MO/CO/Nurse
10.30- 10.50 AM	Tea break	
10.50 - 1.00 PM	Leprosy	MO/CO/Nurse
		MO/CO/Nurse
1.00 - 2.00PM		
2.00 - 4.00 PM	Nutrition	Nutritionist
4.00 - 5.00 PM	Nutrition Exercises	Nutritionist
5.00- 5.20 pm	Tea Break	Pharmacist
5.20- 6.00 PM	Plenary	Coordinator

	Day 4	
Time	Topic	Facilitator
8.00 - 8.20 AM	Recap	Coordinator
8.20 - 10.00 AM	TB Infection Prevention and Control	MO/CO/Nurse
10.00 -11.00 AM	Commodity management	Pharmacist
11.00 -11.20 AM	Tea break	
11.20- 12.20	Commodity management	Pharmacist
12.20 -1.00 PM	Commodity management practical	Pharmacist
1.00 -2.00 PM	Lunch break	Nutritionist
2.00 - 3.00 PM	Community Engagement in TB Activities (ENGAGE TB)	MO/CO/Nurse
3.00 - 4.00 PM	Advocacy and Communication	MO/CO/Nurse
4.00- 5.00 PM	M&E and Data management	MO/CO/Nurse
5.00- 5.20 PM	Tea Break	
5.20 -6.00 PM	Plenary	Pharmacist

	Day 5	
Time	Торіс	Facilitator
8.00 - 8.20AM	Recap	Coordinator
8.20 - 10.30 AM	M&E	MO/CO/Nurse
10.30 AM - 10.50 AM	Tea Break	
11.20 AM - 1.00 AM	M&E Exercises	MO/CO/Nurse
1.00 -2.00 PM	Lunch Break	
2.00PM - 3.00 PM	Social Protection / Other determinants of TB	MO/CO/Nurse
3.00- 4.00 PM	Post-test and Training evaluation	Coordinator
4.00 - 4.30 PM	Closing ceremony	CDH



MODULE 1 - INTRODUCTION









Organization of the Integrated TB, Leprosy and Lung Disease Guidelines

- 1. Practical approach to lung health.
- 2. Core TB: diagnosis and treatment of all forms of TB in children, adults and other special populations.
- 3. Nutrition: highlights the relationship between nutrition lung diseases.
- 4. Advocacy communication and social mobilization in relation to TB, leprosy and lung disease.
- 5. Infection prevention and control of tuberculosis.
- 6. Leprosy: Case detection and management of leprosy
- 7. Commodity management: commodity management and pharmacovigilance.
- Monitoring and evaluation: highlights processes and tools involved in the accurate recording and reporting TB, leprosy and lung disease activities and interventions within the NTLD-Program

MODULE 2 - LUNG DISEASES



























































PUBLIC OF RENYA

- Aims of Treatment
 Prevent complications of
 Asthma
- Maximize quality of life/ health status of patients
- by:
- Clearing symptoms.Enabling normal.
- activity/sports.
- Avoid serious drug SE.

Goals of Treatment

Management of Asthma

- Achieve and maintain control of symptoms
- · Prevent asthma exacerbations
- Maintain lung function as close to normal as possible
- Maintain normal level of activity including exercise
- Avoid adverse effects of asthma meds
- Prevent development of irreversible airflow limitation
- · Maintain normal growth velocity in children
- Prevent asthma mortality







Patient follow up Measure PEF before and after inhaled salbutamol compared with initial best PEF. Find out: How many times per day the patient needed inhaled salbutamol over the last 2 weeks. If patient has visited emergency room or how many times has been hospitalized since the last planned visit. If asthma symptoms have limited activities. Drugs taken each day (If different from prescription, ask patient why).











Distinguishing asthma and COPD

Asthma Likely

- Onset before 20 years of age.
- Associated hay fever, eczema, allergies.
- Intermittent symptoms, with normal breathing in between.
- Symptoms worse at night, early morning, with cold or stress.
- Personal or family history of asthma.
 Asthma likely.
- Confirm diagnosis Give routine asthma care.

COPD likely

- Onset after 40 years of age.
 Symptoms are persistent and worsen slowly over time.
- Cough with sputum starts.
 long before difficult breathing.
- Client is or was a heavy. smoker and had TB.
- Previous diagnosis of COPD.
 COPD likely.
- Confirm diagnosis Give routine COPD care.

Clinical features and diagnosis of COPD

Clinical features

鰦

- Onset after age of 40.
- Symptoms are persistent and worsen over time.
- Cough progresses to difficulty in breathing.
- Sputum production.
- · Previous diagnosis of COPD.

Diagnosis of COPD

- Spirometry is the Gold standard for clinical diagnosis and monitoring COPD.
- Post bronchodilator FEV₁/FVC less than 70% confirms the presence of persistent airflow limitation.
- To diagnosis, manage and follow up COPD patients one should have access to Spirometry facilities.
- Others

· Chest X- ray

Management of COPD Goals of COPD management. To relieve symptoms Prevent disease progression Prevent and treat complications and exacerbations Reduce risk of dying Treatment of COPD Smoking cessation- highest impact in reducing disease progression ٠ Prevention of occupational exposure • Reduction of exposure to indoor pollutants e.g. bio fuels in poorly ventilated houses Physical exercise Pharmacotherapy ٠

REPUBLIC OF KENYA		Pharmaco	otherapy		
	COPD severity classification	Mild COPD	Moderate COPD	Severe COPD	
	Signs and symptoms	Breathlessness with strenuous activity e.g. climbing stairs	Breathless at normal pace e.g. walking	Breathless with activity of daily living e.g. dressing	
	Inhaled beta agonist	2puffs when needed (up to 4 times a day)	2 puffs when needed (up to 4 times a day)	2 puffs when needed (up to 4 times a day)	
	Inhaled Ipratropium bromide (Hospital level)		2 puffs when needed (up to 4 times a day)	2 puffs when needed (up to 4 times a day)	
	Slow release theophylline (Hospital level)			200-300mgtwice day taken long term.	



******* Lung function testing Spirometry Spirometry: Parameters Spirometry • FEV1 -forced expiratory volume in • Is used for the diagnosis one second and assessment of COPD • FVC --forced vital capacity • It is the gold standard test • FEV1/FVC -The percentage of for diagnosing COPD FVC expired in one second It is reproducible. standardized and objective Diagnosis of COPD way of measuring airflow • FEV1/FVC <70% limitation • FEV1<80% predicted (after bronchodilator) confirms the presence of airflow limitation that is not fully reversible

MODULE 3: TUBERCULOSIS































Risk factors for TB infection (exposure)(LTBI)	Risk factors for active TB disease
High prevalence of TB disease in population	Immunosuppression e.g HIV, diabetes, Malnutrition, alcoholism, smoking, immunosuppressant therapy,silicosis
Smear positivity of cases in population (infectivity of cases)	Recent prior infection
Type of TB disease (e.gcavitary, pulmonary more infectious)	Poorly treated previous TB
Proximity and duration to infectious cases (contact)	Extremes of age
Environmental factors e.g poor ventilation, overcrowding	











- 1. **Presumptive TB:** Case is one who presents with symptoms or signs suggestive of TB (previously known as a TB suspect)
- 2. Case of TB: A patient who has been diagnosed with TB in the either one of the following
- A bacteriologically confirmed TB case; one from whom a biological specimen is positive by smear microscopy, culture or WRD (WHO-approved Rapid Diagnostics such as Xpert MTB/ RIF)
- A clinically diagnosed TB case; One who does not fulfil the criteria for bacteriological confirmation but has been diagnosed with active TB by a clinician or other medical practitioner who has decided to give the patient a full course of TB treatment









KENESTEV OF HAALDH	Test	Target Group	Purpose		
	1. Gene Xpert	The first line test for all presumptive TB in; •Children,	For diagnosis of TB		
		HCWs Prisoners, Smear negative persons Previously treatment TB			
	2. Smear microscopy	All presumptive Pulmonary TB	Detect TB disease Monitoring smear positive and gene xpert positive TB		
	(FM & light microscopy)		patients on treatment at months 2, 5 and 6		
	3.Chest X-ray	All presumptive pulmonary TB	Support TB diagnosis especially where sputum for AFB/gene xpert is negative.		
	4.Histology	All presumptive EPTB	Tissue diagnosis in suspected EPTB e.g TB adenitis		
	Other supportive tests				
	5. Tuberculin skin test	Children with presumptive T	B As an adjunct test to detect TB exposure in children, whose TB diagnosis is not obvious. Conducted in tertiary institutions		
	6. ESR	In presumptive TB	Erythrosite Sedimentation Rate (ESR) is usually elevated in active TB. This test is however neither sensitive nor specific enough to be of value in the diagnosis of PTB.		

REPURLIC OF RENYA	• TB diagnosis usir involves collectic • A spot and, • A morning sample	n smear exam ng sputum for ZN an n of 2 sputum samp e	ination Id FM microscopy bles:	
	Sample	When is it collected?	Where is it collected?	
	Spot-1st sample	On the spot when patient presents to facility	In the health facility	
	Morning -2nd sample	Patient collects upon waking up the following morning	At home and brings to health facility (Or in hospital if patient is hospitalized)	













Type of EPTB (3)	Typical Symptoms	Confirmatory tests
TB encephalitis including Tuberculoma	-Headaches -Vonting -Convulsions -Lmb weakness -Cranial nerve paisies	Brain CT scans ; useful in demonstrating lesions Often it is difficult to confirm the diagnosis of brain TB and most patients are treated on an empiric basis
Image: TB of the skin Image: TB of the skin	Lupus vulgaris: Persistent and progressive form of ulaneous TB I occurs as small sharply defined reddish- brown lesions with a galatinous consistency (called apple-jelly nodules) Untreated, lesions persist for years, leading to disfgurennet Scrofulderma: Skin lesions result from direct extension of underlying TB infection of lymph nodes, bone or janits Othen associated with TB of the lungs. Firm, paintes lesions that eventually ulcerate with a granular base. May heal even without treatment but this takes years and leaves unsightly scars.	Skin biopsy: The diagnosis is usualy made or confirmed by a <u>skin biopsy</u> Typical tuberlos are cassating epithelioid granulomas that contain acid-sks baolit. These are detected by tissue staining, culture and polymerase chain reaction (PCR)











	Sources of	TB samples
UNESTRY OF HEALTH	Site	Specimen
	Lungs	Sputum
	Pleura	Pleural Fluid
	Central nervous system	CSF
	Lymphatic system	Lymph fluid, Biopsy
	Genitourinary systems	Urine
	Bones and joints	Synovial fluid
	Whole body (generalized)	Disseminated (milliary TB)







How to establish a specimen referral

network

How to establish a specimen referral network Identify specimen referral coordination and logistics lead at each level Facility, Sub-County, County and Culture laboratories Mapping of all TB treatment and diagnostic facilities Line listing of TB treatment facilities nearest to diagnostic sites (network)

- Identification of a dedicated specimen transport system (Motorbike, bicycle, vehicles, hand delivery, courier e.t.c.)
- · Identification of results feedback






















Transmission of TB bacilli in the laboratory

- The main risks in a TB laboratory are related to the aerosols generated during the procedures that could be inhaled by laboratory workers
- . The risk of aerosolization is associated with the:
 - ✓ Type of procedure
 - ✓ Frequency of testing, and the laboratory's workload
 - ✓ Consistency of the material and its predisposition to aerosolize (for example, viscous liquids versus dry solids)
 - Bacillary load of the materials

New approaches to biosafety are based on risk assessments WHO has adopted an approach that assesses the risks

- associated with different technical procedures performed in different types of
- TB laboratories.
- ✓ Risk-group classifications and containment levels (BSLs) are no longer used.
- ✓WHO's biosafety manual for TB laboratories describes the MINIMUM requirements for facilities, and the practices that can be adopted following a risk assessment



What is a risk assessment?

- A risk assessment is simply a careful examination of what in your work could cause harm to people.
- · A risk assessment must consider:
 - ✓The bacterial load of materials, and the viability of TB bacilli (The route of transmission of TD)
 - ✓The route of transmission of TB
 - ✓Whether the materials handled and the manipulations required for each procedure are likely to generate infectious aerosols
 - ✓The number of manoeuvres in each technique that may generate aerosols
- ✓ The workload of the laboratory and of individual staff members
- ✓The location of the laboratory
- ✓The epidemiology of the disease and the patient population
- ✓ The level of experience and competence of lab staff
- ✓The health of lab staff (especially HIV-positive staff)



Identify potential hazards.

PUBLIC OF KI

- Decide who might be harmed and how.
- Evaluate the risks and decide on precautions:
- Determine the suitability of the physical space
- Evaluate the staff's proficiency in following safe practices
 Evaluate the integrity of safety equipment
- Record your findings and implement any necessary changes.
- Review your assessment and update it when necessary.
- A risk-assessment tool is available at http://www.gliquality.org/



Risk level of TB laboratory	Laboratory activities	Assessment of risk
Low risk	Preparing specimens for smear microscopy or Xpert MTB/RIF testing	Procedures have a low risk of generating infectious aerosols from specimens; the concentration of infectious particles is low

Risk level of TB laboratory	Laboratory activities	Assessment of risk
Moderate risk	Processing and concentrating specimens for Xpert MTB/RIF testing or inoculation onto primary culture media; splitting specimens; direct DST (for example, LPA on processed sputum)	Procedures have a moderate risk of generating infectious aerosols; the concentration of infectious particles is low to moderate

Risk level of TB laboratory	Laboratory activities	Assessment of risk
High risk (TB- containment laboratory)	Culture manipulation for identification; DST or LPA on	Procedures have a high risk of generating infectious aerosols: the
	cultured isolates	concentration of infectious particles is high











	Disinfectants
STRY OF H	Select disinfectants that are effective against mycobacteria based on the material to be disinfected
	✓ PHENOL 2-5% in deionized water is highly irritating, and caution must be used in preparation. It is preferable to use phenolic derivatives:
	 Decontaminate equipment, surfaces and items or liquids before disposal (wear gloves) Prepare the solution daily and leave in contact with the surface for at least 15 minutes to ensure decontamination.
	✓ CHLORINE (sodium hypochlorite, or bleach with 0.72% active chlorine) is an irritant, and is corrosive to metals and plastics:
	 It is a general purpose disinfectant; also can be used to soak contaminated items Allow at least 15 minutes to ensure decontamination
	 Prepare daily and store in a well-ventilated area (toxic gas). Do not autoclave.
	 ALCOHOL 70% leaves no residue but is volatile and flammable (keep far from open flames): Use as a disinfectant on skin (follow by washing with soap) and work surfaces (including metals).
	 PERACETIC ACID leaves no residue, but is stable for only 48 hours after preparation: Rapid action against all microorganisms.

grated Curricul

















Integrated Curriculum	Trends o policies I	n new nave r	v tests and h reduced TAT	ias ˈsi	WHC nce 2	007		
			,	Year	Tech	nology	Turnaroun d time	Sensitivity gain
			Before	2007	Ziehl- micro solid	Neelsen oscopy; culture	<1 day, though often batched 30-60 days	Baseline
		2007	Liquid culture/DST; rapid speciation	15-	30 days	+10% compa with Löwenst Jensen solid cultur	rred ein-	
	2009	LED-b	ased fluorescence microscopy	t b	<1 day, hough often atched	+10% compare with Zieh Neelsen microscop	d I- I Dy	
	Endorsed 2010, updated 2013	×	pert MTB/RIF	V	2 hours	+40% compared with Ziehl Neelsen microscop	н - -	































































RUBUICOFN ******* The aim of TB treatment Main aims of TB treatment: 1. Cure patients, prevent 1. Never use single drugs suffering and death from TB 2. Always use drugs in 2. Prevent long-term complications or sequelae of ΤВ 3. Prevent relapse of the TB weight disease 4. Prevent transmission of the

TB infection

rated Curri

5. Prevent the development of drug resistant TB

-

Basic Principles of TB treatment:

- combinations –using Fixed Dose Combinations (FDCs)
- 3. Drug dosage is based on
- 4. Drug intake should be directly observed
- 5. Ensure the entire treatment is taken as recommended



Classification	Definition			
Pulmonary TB(PTB)	Any bacteriologically confirmed or clinically diagnosed case of TB involving the lung parenchyma or the tracheobronchial tree. This exclude pleural effusion			
Extra pulmonary TB (EPTB)	Any bacteriologically confirmed or clinically diagnosed case of TB involving organs other than the lung parenchyma, e.g. pleura lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges.			

REPUBLIC OF KENYA	Classificatio	on based on history of previous TB treatm (patient registration group)	ent
	Classification	Definition	
	New patients	Patient who has never been treated for TB or has taken anti-TB drugs for less than 1 month.	
	Previously treated patients	Patient who has received 1 month or more of anti-TB drugs in the past. They are further classified by the outcome of their most recent course of treatment as follows: sRelapse patients ; previously treated for TB, declared cured or treatment completed at the end of their most recent course of treatment, and are now diagnosed with a recurrent episode of TB (either a true relapse or a new episode of TB caused by reinfection) D . Toratment <i>Cape Chiltren</i> patients: rescinctive treated for TB and whose treatment fulled at the complete treatment for the complete treatment for th	
		(c) Treatment after name partents, pervoisity deated for 15 and whose iteration raned at the end of their most recent course of treatment (c) Treatment after loss to follow-up patients; previously treated for TB, and declared lost to follow-up at the end of their most recent course of treatment. (These were previously known as return after default patients.)	
	Patients with unknown listed above	own previous TB treatment history do not fit into any of the categories	





Monoresistance Multidrug resistance	Resistance to one first-line anti-TB drug only.	
Multidrug resistance		
	resistance to at least both isoniazid and rifampicin	
Extensive drug resistance	Resistance to any fluoroquinolone and to at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance	
Rifampicin resistance	Resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance to rifampicin, whether monoresistance, multidrug resistance, polydrug resistance or extensive drug resistance	
E	xtensive drug sistance Rifampicin resistance	Stensive drug Resistance to any fluoroquinolone and to at least one of three second-line injectable drugs (capreomycin, kanamycin and amikacin), in addition to multidrug resistance Rifampicin resistance Resistance to rifampicin detected using phenotypic or genotypic methods, with or without resistance to other anti-TB drugs. It includes any resistance, polydrug resistance or extensive drug resistance



Prope	rties of l	ndividua	l anti TE	drugs
Drug	Mechanism of action	Target bacilli	Media	Compartment it works in
Isoniazid(H)	Bactericidal after 24 hours. High potency: kills >90% bacilli in first few days of treatment.	Rapid and intermediate growing bacilli	Alkaline and acid media.	Intracellular and extracellular
Rifampicin(R)	Bactericidal within 1 hour. High potency. Most effective sterilizing agent.	All populations including dormant bacilli.	Alkaline and acid media.	Intracellular and extracellular
Pyrazinamide (Z)	Bactericidal with a low potency. Achieves its sterilizing action within 2-3 months.	Slow growing bacilli	Acid medium.	Intracellular bacilli only (macrophages)
Ethambutol (E)	Bacteriostatic. Low potency. Minimises the emergence of drug resistance.	All bacterial populations.	Alkaline and acid media.	Intracellular and extracellular



EPUBLIC OF KENYA	Anti TB regimen	for use by k children	ooth adult a
		Intensive phase	Continuation phase
	All forms of TB except TB Meningitis and osteo-articular TB	2 RHZE	4 RH
	TB Meningitis and osteo-articular TB	2 RHZE	10 RH
	Directly Observed Therapy a treatment supporter who the patient and to the healt	(DOT) should be is acceptable and th system	e provided using d accountable to

REPUBLIC OF KENYA	Adult dosage of anti-TB drugs according to body weight							
	Drug	Recommended dose in mg/kg	Range in mg/kg	Maximum dose				
	Isoniazid	5	5-10	300mg				
	Rifampicin	10	10-15	600mg				
	Pyrazinamide	35	30-40	1.5g				
	Ethambutol	20	15-25	1.6g				
_	1							

REPUBLIC OF KENYA	FDC treatment dosage for adults								
	FDC Dosages	Formulation	30-39kg	40-54 kg	Over 55 kg				
	Rifampicin 150 mg + Isoniazid 75 mg + Pyrazinamide 400 mg + Ethambutol 275 mg	4-FDC tablet RHZE	2	3	4				
	Rifampicin 150 mg + Isoniazid 75mg	2-FDC tablet RH	2	3	4				

[*] Pediatri	Pediatric dosage of anti-TB drugs accord to body weight							
Drug	Recommended dose in mg/kg	Range in mg/kg	Maximum dose					
Isoniazid	5	5-10	300mg					
Rifampicin	10	10-15	600mg					
Pyrazinamide	35	30-40	1.5g					
Ethambutol	20	15-25	1.6g					



REPUBLIC OF KENYA	Dosage of	pyridoxine	
	Weight (kg)	Dose of pyridoxine (available in both 25mg and 50mg tablets)	
	1-13.9 kg	12.5mg	
	14-25 kg	25mg	
	>25 kg	50mg	







Treatment outcome definitions

- The new treatment outcome definitions make a clear distinction between two types of patients:
 - 1. Patients treated for drug-susceptible TB
 - 2. Patients treated for drug-resistant TB using second-line treatment
 - Defined as combination chemotherapy for drug-resistant tuberculosis which includes drugs other than those in Group 1
- The two groups are mutually exclusive

- Patients found to have drug-resistant TB and placed on secondline treatment are removed from the drug-susceptible TB outcome cohort
- This means that management of the standard TB register and of the second-line TB treatment register needs to be coordinated to ensure proper accounting of the outcomes of treatment

Treatme	nt outcomes for Drug sensitiveTB patients
Outcome	Definition
Cured	A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who was smear or culture negative in the last month of treatment and on at least one previous occasion
Treatment completed	A TB patient who completed treatment without evidence of failure BUT with no record to show that sputum smear or culture results in the list month of treatment and no at least one previous occasion were negative, either because tests were not done or because results are unavailable
Treatment success	The sum of cured and treatment completed. This is calculated based on bacteriologically confirmed cases
Treatment failed	A TB patient whose sputum smear or culture is positive at month 5 or later during treatment
Died	A TB patient who dies for any reason before starting or during the course of treatment
Lost to follow-up	A TB patient who did not start treatment or whose treatment was interrupted for 2 consecutive months or more
Not evaluated	A TB patient for whom no treatment outcome is assigned. This includes cases "transferred out" to another treatment unit as well as cases for whom the treatment outcome is unknown to the reporting unit



Complications of PTB...cont'd

- 3) Fibrosis of the lungs
 Sequelae of extensive tuberculous disease In severe terminal cases, long term oxygen therapy may be required
- · Patients should be referred for review and specialised care by a physician

4) Lung abscess

- Seen in patients with extensive damage to the lungs after tuberculosis
- · Antibiotic treatment is given aided by the results of a pus culture-sensitivity test
- · Surgical intervention may also be necessary

Aspergilloma

 Result from colonization of tuberculous cavities or bronchiectatic lesions with the fungus Aspergilus

Presentation

- · Recurrent or persistent haemoptysis in patient previously treated for TB.
- Malaise
- Fever
- · Chest x-ray shows a cavity with an air crescent (halo) around it
- · High levels of specific immunoglobulin G against Aspergillus in blood (Confirmatory test)

· The only effective treatment is surgical removal of the aspergilloma





Integrated Curriculum Provide Verva Morphology	
All mycobacteria share the characteristic of "acid-fastness," i.e after staining with carbol-fuchsin or auramine-rhodamine, they not decolorize with acidified alcohol	è., ' do
Thus, the common term acid-fast bacilli (AFB) are essentially synonymous with mycobacteria	
 Microscopy therefore, is less useful in distinguishing between various types of mycobacteria 	the

NTM: Associated risk factors and clinical presentation

Associated Risk Factors

- 1. Immunosuppression
- 2. Smoking
- 3. Patients poorly responding to first and second line Anti-TB Therapy
- 4. Previously treated TB patients
- 5. Presence of underlying lung disease

Clinical presentation

- Very similar to PTB-impossible to distinguish clinically
- Symptoms thus may include:
 - Chronic cough dry, productive or hemoptysis
 Fever
 - Night sweats
 - Weight loss-wasting
- Suspect atypical organisms in patients with history of previous TB treatment (with adherence), with no or poor resolution of symptoms





Mycobacterium species	Drugs to be used	Duration
Mycobacterium Avium complex	Nodular/bronchiectactic disease: Clarithromycin Igm/Azithromycin 500mg, Rifampin 600 mg and Ethambutol 15-25mg/kg, thrice weekly or daily, +/-amikacin/streptomycin in the first 2-3 months	-Treat until culture negative on therapy for 1 year
	In HIV co-infection: Substitute rifampicin with rifabutin, daily clarithromycin or azithromycin with ethambutol. Add streptomycin/amikacin if no response Prophylaxis for all with low CD4 count less than 50 Clarithrown in Is daily or azithromycin Is	-In HIV give prophylaxis till CD4 above 100
	weekly OR a fluoroquinolone if macrolide resistant MAC	
M. Fortuitum	 Any 2 of the following drugs: Amikacin, fluoroquinolones, sulfonamides, imipenems, linezolid, cefoxitin or clarithromycin 	-6-12 months, until cultures are negative
	 Debridement of cutaneous ,lung or other foci of infection and removal of implants 	
M. malmoense	Not very responsive to treatment Clarithromycin, rifampicin and ethambutol had batter treatment and loss monthlits	-At least 2yrs

	Management of NTM								
Mycobacteriu m species	Drugs to be used	Duration							
M. Abscessus	Extremely difficult to eradicate- Multidrug regimens (that include clarithromycin lg/day and intermittent courses 2 or more drugs of the following drugs: amikacin, impenem, eefoxitin, tigecycline, fluoropuinolones, doxycycline or linezolid) is recommended may cause symptomatic improvement and disease regression. Surgical resection of localized disease combined with multidrug clarithromycin-based therapy offers the best chance for cure of this disease.	-4-8 weeks of IV drugs then 6-12 months of per oral (P.O) regimen -Treat until sputum is culture negative							
M. Kansasii	 Drug susceptible strains- RHZE (use conventional anti-TB doses) Rifimpicin resistant isolates-use any 2 of clarithromycin[l^a option) or a fluoroquinolone (if macrolide resistance noted), sulfamethoxazole or streptomycin and ethambulol 	-Until sputum cultures negative for more than 6 months							
M. szulgai	Responds to treatmentCombinations of rifampicin, ethambutol and clarithromycin	-Until cultures are negative							























C OF KENYA		
CENTRAL CONTRAL CONTRA		
Collaborative TB/HIV	activities	
Objective/ Activity	Implementer	
A. Establish the mechanism for collaboration	TB and HIV Programs	_
1. TB/HIV coordinating bodies 2. HIV surveillance among TB patient		
3. TB/HIV planning 4. TB/HIV monitoring and evaluation		
B. To decrease the burden of TB in PLHIV- Three Is 1. Intensified TB case finding	HIV program	
2. Isoniazid preventive therapy 3. TB infection control in health care and other settings		
C. To decrease the burden of HIV in TB patients	TB program	
2. HIV prevention		and the second se
4. HIV/AIDS care and support		1000
5. Antiretroviral therapy to TB/HIV co-infected patients		













Integrated Curriculum REFUELC OF KENYA	Tools fo	or ca	rryi	ng	ou	it I	CF	: A	dult			
	*	AD	Minist	y of Health	h (Febru	20140		6	0			
	Pattent Unique Na	Nas Age:	Seg: o Male red landsarch Frestanest Suppor	cifenate er's Cell phone	Weight a Number	(Kg) Combert is	hydromr					
	Date 1. Cough of any distance (V/N) 2. Forcer (V/N) 2. Forcer (V/N) 4. Single transition (V/N) 4. Night versus (V/N) 6. Single transition (V/N)	J. F. J. F.	a h a h	J F J		F - J - F	-1 - F	e er GeseNp				
	If "No" is all queries, in Indian the Artikin taken Artikin taken Date Spaten course: Clear Xpart (Pass Neg) Clear Lang, Dismail N (Engenities X) Hart and TB (CN) Evolution for DTT (CN) Evolution for DTT (CN) Evolution for DTT (CN)		. 2 % 3		J 7. J	7. 2	660x.	1 1	J & J &			
	Ash for the following 1. Yoldow (observed union 2. Neuroleneous) Domain (our controls (XS) Examine for the following 1. Yoldowness of even (XS) 2. Touchersees (XS) 3. Lever mercine inter evene (X) 3. Lever mercine inter evene (X)	(X170) as the hands or first quadrant of the available;	.4.7		En Col	Contraster (1 nef aspikted a To Fellerar E continued* d moferred Out	5+6-1) (r		Das		(Sec.	and and a
	If the offerst has any of the above history the analysis of the constraints and re-evalue of an to obtain the constraints (VT and re- Data started on IFT On AET: (VN) If we AET, data started AET.	er examination fire e on next visit, cost outbutton on m	AST		*86 Add Add OB	racon for disc rense dang reas ree Til diseas are	ontionation dom		(Tuky)			\mathcal{O}











PUBLIC OF RENYA

Contraindications for IPT

1.Active TB disease

2.Active hepatitis (acute or chronic)

- 3.Symptoms of peripheral neuropathy (Numbness or tingling sensation, regression in motor milestones refusal to crawl, walk, run or reduced playfulness).
- 4.Contacts of Drug Resistant TB (DRTB)

NB.

- If the client has any of the above contraindications, defer IPT: manage the underlying condition and re-evaluate on next visit.
- Avoid alcohol consumption due to increased risk of hepatotoxicity

INH and Pyridoxine dosing · Isoniazid is given for 6 months at a dose of 10mg/kg, up to a maximum of 300mg. . · If available, pyridoxine should be given alongside Isoniazid to reduce the risk of peripheral neuropathy Dose of pyrig Weight (kg) umber of tablets o pyridoxine (50mg) Weight Dose in mg Number of 100mg INH tablets Number of 300 (Adult) tablet 1-13.9 kg Quarter tablet daily 14-25 kg Half a tablet daily >25 kg One tablet daily Adults One tablet daily All children on IPT should have their weight taken at every visit and INH dosage adjusted





Adult ICF/IPT card (back)- IPT monitoring Hepatotoxicity? Peripheral Does the patient Adherence Measurement (vomiting, right Neuropathy have Rash? IPT due Wt Good = missed < 2 doses / Date upper quadrant Does client have any date collected month (kg) of the following in the abdominal pain, IPT Fair = missed 2-4 doses / yellow urine or limbs? month Numbness, tingling eyes) Bad = missed ≥5 doses / or burning sensation month Yes (state No Yes (state Yes (state No Good Bad (state action No action action taken action Or Fair taken) taken) taken) e.g. decision made to stop IPT, adherence counseling, etc) Ea Fair no ۱O no 4/5/15 4/5/15 55kg

IPT due date	Date collecte d IPT	Wgt (kg)and actual dose of INH in mg	Hepatota (Signs & sympton vomiting persister irritability abdomin pain, yel or eyes (oxicity ns) , nt ,, al, RUQ low urine	Peripheral I (Signs & syr (Older child numbness, 1 Younger chi regression ii milestones r crawl, walk,	Veuropathy nptoms) – ingling, Id- n motor efusal to run)	Does th patient Rash?	ne have a	Adherend Measuren Good = n doses / m Fair = mis 4 doses Bad = mis doses / m	ce ment nissed < 2 nonth ssed 2 – / month ssed ≥5 nonth
			Yes (state action taken)	No	Yes (state action taken)	No	Yes (state action taken)	No	Good or Fair	Bad (state action taken)
E.g 2/04/15	2/04/15	13kg		No		No		No	Good	

Management of ADRs-Hepatitis

 If a patient on IPT presents with signs and symptoms of hepatitis; (yellowness of eyes, RUQ pains, vomiting etc)

Management;

- Check for other causes of hepatitis ; Test for Hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV).
- Check LFTs
- If liver enzymes < 3x with symptoms, or <5 times normal without symptoms, continue INH but monitor LFTs every week.
- If liver enzymes are > 3x with symptoms, or >5 times normal without symptoms STOP INH and repeat liver function tests weekly.
- Consult further.

Management of ADRs-Peripheral neuropathy

 If patient develops signs of peripheral neuropathy(numbness, tingling sensations etc)

Management

- administer pyridoxine at 100mg with close monitoring
- If patient develops motor symptoms, stop INH
- · For rash, monitor closely.
- If worsens, temporarily stop INH
- If rash is severe, or associated with reddening or peeling of mucus membranes, (Steven Johnson Syndrome) - stop INH immediately and admit

Management of patients developing TB while on IPT

- If a patient screens +ve during ICF, gene Xpert is the preferred test for diagnosis of TB if available
- If not available, conduct sputum microscopy and CXR if sputum is negative
- DST and culture should also be conducted for all patients who develop TB while on INH
- If drug susceptible or resistant TB is identified treat as per national guidelines
- If EPTB is suspected during IPT, investigate and manage as per national guidelines

Management of defaulters or those discontinued from IPT						
Scenario	Action					
If patient had discontinued INH for less th 1 month	an Conduct adherence counseling, Conduct ICF and if asymptomatic Continue from where they left off Ensure they have completed a 6 month course					
If a patient had taken INH for less than 1 mon in total and discontinued for any reason (li toxicity or loss to follow up)	th Conduct adherence counseling, Address reasons for discontinuation Conduct ICF and if asymptomatic Restart INH afresh Ensure they have completed a 6 month course					
If patient had discontinued INH for more th 1 month but less than 3 months	n Conduct adherence counseling, Conduct ICF and if asymptomatic Restart INH Ensure they complete a 6 month course within a 9 month period					
If patient discontinued for more than 3 mont or had discontinued more than once	is, Do not re-initiate IPT					





Commodity management for IPT

 Facilities to order and receive an initial 6 months supply of INH for initiating patients identified

- The INH refill TCA to align with ARVs TCA refill schedule i.e. if client is dispensed 2 months of ARVs then they receive 2 months of INH
- Revised ART LMIS tools i.e. DAR ARVs and Ols, F-CDRR and F-MAPS to be used to document consumption and reporting in the CCC where INH for HIV positive population will be dispensed.
- Dispensing of INH to the HIV positive clients will be at the CCCs and for the TB exposed HIV negative clients will be at the TB clinic.

- Dispensing for the TB negative children exposed to TB to be documented in TB-DAR
- ADRs of patients on INH be reported using the usual PV tools (yellow form)
- Receiving and storage of INH to follow the same procedure as for ARVs i.e. received by the pharmacist, and stored along with ARVs and other OI medicines in the drug store
- The TB clinic will source INH 100mg stocks from the health facility pharmacy periodically and will document quantities, dispensed on the DAR

REPUBLIC OF KENYA

Monitoring & Evaluation: Documentation

Screening

 All PLHIV, children <5 exposed to smear positive TB and prisoners shall be screened for TB using ICF/IPT tool.

IPT Initiation.

- The IPT /ICF card shall be updated by the clinician at the start of IPT and at every visit.
- The facility M&E staff (data clerk) will record all PLHIVs started on IPT in the CCC IPT register, and at every subsequent visit made for IPT refills.
- The TB clinician/nurse will record all children under the age of 5 started on IPT in the TB clinic's IPT register, and at every subsequent visit made for IPT refills.

The IPT registers will be recorded such;

- Serially record all patients in the IPT register beginning each calendar year, (the number should indicate a serial number and year e.g. 1/15).
- Indicate the IPT serial number in the ICF/IPT tool and the MOH 258(appointment card) for PLHIV and ICF/IPT card for children < 5 exposed to smear positive TB.
- At the end of every month, draw a line to close the month and summarize the month as per criteria provided at the bottom of the IPT register (Total started on IPT during the month disaggregated by age < 15 and 15+).
- The Facility serial numbers in the IPT register shall be continued in the following month.
- For Each Month, Identify the cohort 12 months since the IPT start date and Indicate their 12 months outcomes. (Use the codes provided at the bottom of the register)

New serial numbers shall be initiated in the beginning of the following calendar year.

• At the end o • To tally the the MOH

- At the end of the reporting period CCC data clerk,
 - To tally the entries in DAR and IPT register using the MOH C&T tally sheet
 - The Totals from tally sheet shall be transferred to MOH 731
- · At the end of reporting period in TB clinic
 - SCTLC to document all < 5 exposed to smear +ve TB who received IPT in reporting period, report monthly totals to TIBU
 - HCW at the TB clinic to summarize the monthly IPT totals and transfer the totals to MOH 711



***** Cotrimoxazole preventive therapy (CPT)** Cotrimoxazole preventive therapy (CPT) reduces mortality among TB patients with HIV irrespective of CD4 count. • CPT should be provided to all TB/HIV co infected individuals (unless contraindicated). All patients should be monitored for side effects including rash and gastrointestinal disturbance. Cotrimoxazole should be withdrawn whenever moderate to severe reactions occur.

• This is HIV testing initiated by a health worker as part of the diagnostic work up for patients who present with symptoms or signs that could be attributable to HIV disease. This will offer an entry point for all TB patients to quality and Sites for PITC will depend on several factors within the institution including but not limited to workload, space for testing and human resources available. · Ideally all TB patients should be counseled tested within the TB (chest) clinic to ensure integrated services.

Weight in kg	Cotrimoxazole syrup	480 mg (Single	960 mg (Double	
	(mg per ml)	Strength) tablet	strength) tablet	
1.0 - 4.9	2.5mls	1/4 tab	-	
5.0 - 8.9	5mls	½ tab	1⁄4 tab	
9.0 - 16.9	10mls	1 tab	1/2 tab	
17.0 - 30.9	15mls	2 tab	1 tab	
>30.9 (adults and adolescents)		2 tab	1 tab	

Dose of cotrimoxazole for CPT

Dapsone is recommended in patients allergic to Cotrimoxazole(CTX) and is used only in patients with WHO stage 4 disease and /or those with a CD4 <200 cells /mm3.





Treatment of TB/HIV co infected patients

- The principles of treatment of tuberculosis in HIV-infected patients are similar to those in HIV-negative TB patients, and the same regimens should be used in both groups.
- · Response to TB treatment may be slower in PLHIV.
- All PLHIV co-infected with TB should receive co-trimoxazole prophylaxis as well as antiretroviral therapy.
- Nutritional support is often needed for patients with low BMI
- The management of PLHIV co infected with TB/HIV should be integrated so that all family members are counseled and tested for HIV, screened for TB and managed appropriately.
- ARVs should be initiated within **2-8 weeks** of starting anti-TB therapy.

Immune re-constitution inflammatory syndrome (IRIS)

- This is a paradoxical deterioration after initial improvement following treatment initiation.
- It is seen during the initial weeks of TB treatment with initial worsening of symptoms due to immune re-constitution.
- Management: Continue anti-TB therapy: give non-steroidal anti-inflammatory drugs until severe symptoms subside.
- Give prednisone at 2mg/kg once daily for 4 weeks, and then taper down over 2 weeks(1mg/kg for7days, then 0.5mg/kg for 7 days)










REPUBLIC OF KENYA	Ritonavi r ir	r Dosing for n Children 1	r Super-Boo Faking Rifan	sting LPV/	
	Weight Range (kg)	Lopinavir/ritonavir (LPV/	r)	Additional dosing of ritonavir for children taking rifampin	
		Twice Daily	Twice Daily	Twice Daily	
		Lopinavir/ ritonavir 80/20mg/ml solution	Lopinavir/ ritonavir 200/50mg tablets	Ritonavir liquid (80mg/ml, in 90 ml bottle) Ritonavir dose is adjusted to nearest mark for the ease of measurement	
	3 - 5.9	1 ml	-	1 ml	
	6 - 9.9	1.5 ml	-	1 ml	
	10 - 14.9	2 ml	-	1.5 ml	
	14 - 19.9	2.5 ml	1 tab twice daily	2 ml	Sec. 1
	20 - 24.9	3 ml	1 tab twice daily	2.5 ml	(h
	25 - 34.9	4 ml	2 tab in am & 1 tab in pm	4 ml in am & 2 ml in pm	aler.

















Monitoring and evaluation

- There should be quarterly collection of data on service use. This will allow changes in the sub county TB/HIV service performance to be monitored.
- Indicators for new activities should also be monitored and reported guarterly.
- Six monthly and yearly evaluations should be undertaken including quarterly meetings where lessons learned can be exchanged.
- Documenting the process
- The coordinator of the sub county collaborative activities should be responsible for documenting the process of planning and implementing collaborative TB/HIV activities including the resources required.







Category	Number/%
Total TB cases	81,518
Total child cases	8.5%
Tested for HIV	94%
HIV positive	27%
CPT uptake	99%
ART uptake	95%

REPUBLIC OF KENYA	Child TB t	rends		E.
	Year	Total TB cases	Child TB cases	% of total cases that are child TB cases
	2013	90,692	8,649	9.5%
	2014	90,091	8,517	9.5%
	2015	81,518	6,968	8.5%



Pathogens found in lungs from autopsy studies of African children

Causes of pneumonia	HIV-infected N=473	HIV-uninfected N=338	Total N=811
Bacterial	238 (50%)	132 (39%)	370 (46%)
PcP	145 (31%)	11 (3%)	156 (19%)
CMV	121 (26%)	7 (2%)	128 (16%)
M.tuberculosis	50 (11%)	27 (8%)	77 (9%)
Co-infection	98 (21%)	5 (1.5%)	103 (13%)

Combined data from 7 autopsy studies from five TB endemic countries shows that tuberculosis is a common diagnosis in children dying with lung disease including HIV-uninfected children















REPUBLIC OF NEWL	Age-specific risk disease in Imn	for progression to active nune Competent Children	тв
	Age at Primary Infection	Total % Progressing to TB disease	
	< 1 year	50	
	1–2 years	20 – 30	
	2–5 years	5	
	5–10 years	2	
	>10 years	10 – 20	

Immuno-suppression as a risk factor for TB disease

Various immune-suppressed children are at high risk of progressing to TB disease due to the inability of their immune system to prevent multiplication of the TB bacilli. Examples include:

- HIV (the lower the CD4 the higher the risk)
- Malnutrition
- Post-measles (depressed cell mediated immunity for months after measles)
- · Children with malignancies
- Chronic diseases requiring long term steroid treatment







History of contact • History of contact with an adolescent or adult with proven or suspected TB

- Close contact is defined as living in the same household as or in frequent contact with smear positive PTB index case
- Ask about anyone in the household/dormitory/classroom/ school transport with chronic cough. If present request assessment of that person for possible TB
- Most children will develop TB within one year of exposure



Atypical clinical presentations of PTB

Acute severe pneumonia

-

- · Presents with respiratory distress and crackles
- Occurs especially in infants and HIV-infected children
- Suspect PTB if response to antibiotic therapy is poor. If child is HIV infected also suspect other HIV-related lung disease e.g. PCP

Wheeze

PERIOD TO OF KI

- Asymmetrical and persistent wheeze can be caused by airway compression due to enlarged tuberculous hilar lymph nodes
- Suspect PTB when wheeze is asymmetrical, persistent and nonresponsive to bronchodilator therapy



Bacteriological in	vestigations*	
Laboratory test	Target	Purpose
MTB/Rif GeneXpert	 The first line test for all presumptive or suspected TB in Infants, children and adolescents Surveillance for Drug Resistant TB among children previously treated for TB, child contacts of DRTB patients, refugees, prisones, children not improving on first line TB treatment 	For diagnosis of TB To determine rifampicin susceptibility Done for child specimens of sputum, CSF, Gastric aspirate, Nasopharyngeal aspirates, Pleural fluid, Pericardial fluid, Ascitic fluid, FNA
Smear microscopy (Fluorescent and Light microscopy)	Infants, children and adolescents with presumptive Pulmonary TB	Only used in situations where Xpert is not accesible Monitoring smear positive and/or gene xpert positive TB patients on treatment at months 2, 5 and

Radiological inv	Radiological investigations					
X-ray	Chest Xray for all infants, children and adolescents with presumptive TB Xrays of the affected bone, joint, spine as appropriate	Diagnosis of TB and EPTB in all children where xray services are available For children obtain Anteroposterior and lateral CXF views				
Ultrasound	Abdominal ultrasound Chest ultrasound	Diagnosis of abdominal TB Detection of pleural effusion				
CT Scan or MRI	Head CT, Chest CT as needed MRI of the abdomen, head, chest or spine as needed	Evaluation of severe or complicated cases				

Tuberculin skin test	Children	Useful test to detect TB exposure in children and support presumptive clinical diagnosis in situations where there is no obvious close TB contact to the child
Interferon gamma reaction	Children	Similar role to TST but more expensive.

Laboratory Test	Target	Purpose	
Line Probe Assay (LPA)	Children who are: • MTB positive rifampicin sensitive, and are at high risk for DRTB • MTB positive rifampicin resistant, and are either high or low risk for DRTB	To determine if isoniazid resistance is present	
Culture and DST	 Children who are: Eligible for LPA should also have a culture and DST requested Children with clinically suspected TB whose Xpert is negative Children who are on treatment for TB who are failing to respond to therapy 	To diagnose TB To determine the drug sensitivity pattern To diagnose infections with non- tuberculous mycobacteria	
Histology	All presumptive extra-pulmonary TB where FNA is indeterminant	Tissue diagnosis in suspected EPTB e.g TB adenitis	

Investigations

GeneXpert

- This is the preferred test for diagnosis of TB among children
- It is done for Sputum, gastric aspirate, CSF and bronchial secretion specimens
- Specimens from children who cannot expectorate can be obtained through a gastric aspirate

Sputum microscopy

· Where GeneXpert is not available, the sputum specimen can be evaluated using sputum microscopy.



Investigations.....2

Chest Xray

- TB may present with diffuse disease in younger children and an adult-like cavitary picture in older children.
- Radiological features suggestive of PTB will include:
 - Persistent lung opacification especially if focal
 - Enlarged hilar or subcarinal lymph nodes. In children below 6 years of age, mediastinal widening may be due to the thymus gland
 - Diffuse micronodular infiltrates (miliary pattern)
 - · Pleural effusions
 - · Upper lobe opacification with or without cavities especially in adolescents



Common cause for a widened mediastinum in a young child is a large thymus which causes the sail sign on the chest radiograph (see arrow).

Suspected hilar and paratracheal lymph gland enlargement. The diagnosis can be made with more certainty when a lateral chest radiograph is examined as well



enlargement visible on the lateral chest radiograph. The arrow indicates the hilar lymph glands.



ALGORITHM F	FOR DIAGNOSIS OF TUBERCULOSIS IN CHILDREN
History of presenting illness	For all children presenting to a health facility ask for the following suggestive symptoms: Cough, fever, poor weight gain, lethargy or reduced playfulness Suspect TB if child has two or more of these suggestive symptoms.
	Ask for history of contact with adult/adolescent with chronic cough or TB within the last 2 years
Physical examination	Examine the child and check for: •Temperature > 37.5 (fever) •Weight (to confirm poor weight gain, weight loss) - check growth monitoring curve) •Respiratory rate (fast breathing) •Respiratory system examination – any abnormal findings
Investigations	Examine other systems for abnormal signs suggestive of extra-pulmonary TB Obtain specimen* for Xpert MTB/RIF (and culture when indicated**) Do a chest Xray (where available) Do a Mantoux test*** (where available) Do a HIV test Do other tests to diagnose extra-pulmonary TB where suspected

Diagnosis	Bacteriologically confirmed TB: Diagnose if specimen is positive for MTB	Make a Clinical Diagnosis of PTB if: Child has two or more of the following suggestive symptoms: -Persistent cough, fever, poor weight gain, lethargy PLUS two or more of the following: -Positive contact, abnormal respiratory signs, abnormal CXR, positive Mantoux Note: If child has clinical signs suggestive of EPTB, refer to EPTB diagnostic table		
Treatment	Treat for TB as follows: •All children with bacteriologically confirmed TB •All children with a clinical diagnosis of TB			
	NB: Children who do not have an should be treated for TB All forms of TB (Except TB menin TB meningitis hone and inint TB	Xpert result; or their Xpert result is negative but they have clinical signs and symptoms suggestive of IB rights, bone and joint TB): Treat for 6 months (2 RHZE / 4 RH) Treat for 12 months (2 RHZE/ 10 RH)		
*Specimen may i Attempt to obtai	nclude: Expectorated sputum (child > 5 years), induced sputum, nasopharyngeal aspirate and gastric aspirate.		







Treatment of Tuberculosis in children Children usually have paucibacillary disease Children develop extra-pulmonary TB (EPTB) more often than do adults Severe and disseminated TB (e.g., TB meningitis and miliary TB) occur especially in young children (less than 3 years old)

 Treatment outcomes in children are generally good even in the HIV infected provided treatment is started promptly. However, response to treatment in this category may be slow





- · Classify the case of child TB before starting treatment into pulmonary or extrapulmonary TB
- Record the TB diagnostic category, treatment regimen and date anti-TB treatment was started on road-to-health book as well as on TB treatment card and facility TB register
- A caregiver should be identified as the DOT supporter for all ages including older children. Educate the DOT supporter on anti-TB regimen and adherence
- · Take the child's weight at each visit and record

- Calculate drug dosages at every visit according to the child's current weight (note that children gain weight while receiving anti-TB treatment)
- Once treatment is started it must be completed; "trial of TB treatment" should never be used as a diagnostic tool

RECOMMENDED TB TREATMENT REGIMEN TB disease category Recommended regimen Intensive phase Continuation phase All forms of TB except 2^{*} RHZE 4 RH TB meningitis, bone and joint TB (osteoarticular TB) 2 RHZE TB meningitis 10 RH

Osteoarticular TB Drug resistant TB Refer to a DRTB specialist

Use of Ethambutol in children · Ethambutol is now recommended as fourth drug in intensive phase of first-line regimens and can be safely used at recommended dosages in all ages The risk of toxicity is negligible for children of any age when Ethambutol is used at recommended dosages of 20(15-25) mg/kg/day Dosage should not exceed 25mg/kg/day · Risk of toxicity is dose-related

IBLIC OF KENN	* DO	SAGE	S FOR	A CHILD \	NEIGHI	NG UP	
RY OF HEALT	п			0 3.9 KG			
				Number of tablets			
	Weight bands		Intensive Pha	se	Continu	ation Phase	
	(Kg)	RHZ (75/50/150mg)	E(100mg)	How to reconstitute the medicines	RH(75/50mg)	How to reconstitute the medicines	
	Less than 2 Kg	1/2/00/10/mg/	14	Dissolve one (1) lablet of RHZ in 20 ml of safe drinking water. Once fully dissolved, add the completely crushed one (1) lablet of Ethambutol and give <u>5ml (114)</u> of this solution	14	Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully dissolved, give <u>5ml (14)</u> of this solution	
	2-2.9	1/2	1/2	Dissolve one (1) tablet of RHZ in 20 ml of safe drinking water. Once fully dissolved, add the completely crushed one (1) tablet of Ethambutol and give <u>10ml (1/2)</u> of this solution	14	Dissolve one (1) tablet of RH in 20 mi of safe drinking water. Once fully dissolved, give <u>10 mi (1/2)</u> of this solution	
	3-3.9	%	%	Dissolve one (1) tablet of RHZ in 20 ml of safe drinking water. Once fully dissolved, add the completely crushed one (1) tablet of Ethambutol and give 15ml (3/4) of this solution	%	Dissolve one (1) tablet of RH in 20 ml of safe drinking water. Once fully dissolved, give <u>15ml (3/4)</u> of this solution	



Dosage	For Paediat	ric TB Tr mulation	eatment ns)	
		Number of Tablets		
	Intensive	Phase	Continuation Phase	
Weight Bands (Kgs)	RHZ (75/50/150mg)	E(100mg)	RH(75/50mg)	
4 - 7.9	1	1	1	
8 - 11.9	2	2	2	
12 - 15.9	3	3	3	
16 - 24.9	4	4	4	
25 kg and above	Use adult dosages and preparations			
CHILD ABOVE 25	KG: ADULT DRUG F	ORMULATION	N DOSAGE TABLE	
	Internetive Diverse	Number of Tablets	antinuation Dhase	
	RHZE (150/75/400/275	mg)	RH(150/75mg)	
Weight Bands (Kgs)				
Weight Bands (Kgs) 25 – 39.9	2		2	
Weight Bands (Kgs) 25 – 39.9 40 – 54.9	2 3		3	

Weight (Kgs)	Dose in mg	Number of 25mg tablets	Number of 50mg tablets
<5	6.25 mg	Half a tablet 3 TIMES PER WEEK	Not suitable for young infan
5.0 – 7.9	12.5 mg	Half a tablet daily	Half of 50mg tablet 3 TIMES PER WEEK
8.0 - 14.9	25 mg	One tablet daily	Half of 50mg tablet daily
15.0 kg and above	50 mg	Two tablets daily	One 50mg tablet daily





At every follow up visit:

- Weigh the child. Document the weight and adjust dosage if necessary
- Explain and emphasize to care-giver and child why they must take the full course of treatment even if they are feeling better (adherence counseling)
- Note risk factors for poor adherence such as long distance to health facility, lack of/transport costs, orphan (especially if mother has died) or primary care-giver unwell and adolescents, TB/HIV comorbidity
- Explain that anti-TB drugs in children are well tolerated and safe
- CXR is not required in follow-up if the child is responding well to anti-TB treatment. If a child had an abnormal CXR at diagnosis, a repeat is done at the end of TB treatment



Causes of poor response to treatment

- Poor adherence; this is the commonest cause. If uncertain, a child can have health care worker DOT at the health facility
- HIV infection

- Wrong diagnosis
- · Other concurrent chronic lung diseases
- Under-dosage of drugs
- Resistant form of TB
- Complications e.g. neurological complications, bronchiectasis e.t.c.



RY OF HEALTH					
	ADR	PRESENTATION	LIKELY DRUG	MANAGEMENT	
	Hepatitis	-Nausea and vomiting if mild -Jaundice & tender hepatomegally if severe	INH, RIF, PZA	Stop the anti-TB drugs immediately and refer to hospital	
	Peripheral neuropathy	-Worse in malnutrition and TB/HIV co-infection -Tingling, numbness, weakness or reduced playfulness	INH	Supplemental pyridoxine	
	Optic neuritis	Reduced vision, blue-green color blindness	ЕМВ	Ensure correct EMB dose Stop Ethambutol Refer for further management	
	Rash	-Mild -Severe (involves mucous membranes)	INH, RIF, PZA, EMB	Mild-give antihistamines Severe. Stop anti-TBs and refer	(









Dose of Isoniazid (INH) for Isoniazid Preventive Therapy (IPT) in children

Weight (kg)	Daily Dose in mg	Number of 100 mg tablets
<5	50	1/2
5.1 – 9.9	100	1
10-13.9	150	11/2
14-19.9	200	2
20-24.9	250	21/2
>25	300	3*

Follow up for children on IPT Children on IPT should receive monthly follow up During each follow up visit: Give adherence counseling Screen for TB disease i.e. persistent cough, fever, lethargy, poor weight gain Monitor INH adverse effects Update the patient details in the IPT register



111

Introduction to TB/HIV in children

- HIV infection is one of the risk factors associated with development of Tuberculosis in children
- HIV infected children may have multiple and concurrent opportunistic lung infections that clinically present like TB, thus making the diagnosis of TB in a HIV infected child more difficult
- The ARVs and anti-TB drugs have potentially significant drugdrug interactions as well as overlapping toxicities
- Therefore comprehensive approach to management of both TB and HIV is critical













Differential diagnosis of chronic respiratory symptoms in HIV infected children

Differential Diagnosis	Clinical features	
Recurrent pneumonia	Recurrent episodes of cough, fever and fast breathing that usually respond to antibiotics	
Lymphoid Interstitial Pneumonitis	Slow onset cough associated with generalized symmetrical lymphadenopathy, finger clubbing, parotid enlargement. Nutritional status variable, mild hypoxia, CXR: diffuse reticulonodular pattern andbilateral perhiharadenopathy	
Pneumocystis Jirovecii Pneumonia	Common cause of acute severe pneumonia, severe hypoxia especially in infants. Unusual after 1 year	
	CXR: diffuse interstitial infiltration, hyperinflation	
Tuberculosis	Persistent respiratory symptoms not responding to antibiotics. Often poor nutritional status; positive TB contact especially in younger children	
	CXR: focal abnormalities and peri hilar adenopathy	
Bronchiectasis	Cough, productive of purulent sputum, halitosis, finger clubbing, seen in older children. CXR: honeycombing usually of lower lobes	
	Complicates recurrent bacterial pneumonia, LIP or TB	
Mixed infection	Common problem: LIP, bacterial pneumonia, Consider TB when there is poor response to first-line empiric management	
Kaposi' s sarcoma	Uncommon	
	Characteristic lesions on skin or palate	

Principles of TB treatment in HIV-infected children are similar to those in HIV-negative children The same regimens should be used as those used in HIV negative children Response to TB treatment may be slow in PLWHA Nutritional support is often needed for children with TB/HIV The management of children with TB/HIV should be integrated so that all family members are counseled and tested for HIV, screened for TB and managed appropriately



CPT in TB/HIV co-infected children

- Cotrimoxazole reduces mortality among children infected with HIV
- All children with TB/HIV should be initiated on Cotrimoxazole as soon as possible
- The duration of treatment is usually life-long with a once daily dosing
- The children should be monitored for side effects
- CPT should be discontinued if a child develops severe adverse reactions













Child contacts of infectious MDR-TB cases

- MDR TB child contacts should receive careful clinical followup for a period of at least 2 years
- If active disease develops, prompt initiation of treatment of the child with a regimen designed to treat MDR-TB is recommended
- The regimen is usually based on the resistance pattern of the MDR TB index case
- The use of second-line drugs for chemoprophylaxis in MDR-TB contacts is currently not recommended















- · They include:
 - · Local abscesses at the injection site

- · Secondary bacterial infections
- · Suppurative adenitis in the regional axillary lymph node
- Local keloid formation
- Disseminated BCG disease. Consider it if axillary node enlargement is on the same side as BCG in a HIV- positive infant and treat as TB
- Most reactions will resolve spontaneously over a few months and do not require specific treatment

















Injecting the tuberculin

- A tense, pale wheal that's 6 to 10 mm in diameter appears over the needle bevel. If not, repeat the injection at a site at least 5 cm (2 inches) away from the original site
- Remove the needle without pressing or massaging the area
- Discard the used syringe immediately in the designated puncture-resistant container
- In case a drop of blood appears at the injection site, lightly blot the blood away with a gauze pad or cotton ball
- Do not cover the site with an adhesive bandage because the adhesive could cause irritation and interfere with the test
- Immediately and thoroughly wash your hands

After the injection

· Write the date and the time the test was administered, the name and manufacturer of the injected solution, the lot number, the tuberculin dose administered, the expiration date, the forearm or alternative site in which the injection was given, the site location if you repeat the test, the name of the person who administered the test, and the reason for giving the skin test

· Remind the patient to return.

- · Explain how to care for the injection site after the test
- Return the tuberculin vial to the refrigerator, or other cooling container

** **Reading and interpretation**

- The results should be read 72 hours Place "0" of ruler line on the after administration
- Visually inspect injection site under good light and on a firm surface
- Use fingertips to find the margins of induration which is a hard, dense, raised formation
- Mark induration and measure across the forearm; from the thumb side of the arm to the little finger side of the arm or vice versa.
- inside-left edge of the induration
- Read ruler line on the inside-right edge of the induration (use lower measurement if between two gradations on mm scale)
- Record the measurement in millimeters
- If no induration, record as 0 mm
- · Do not record as "positive" or "negative"

Interpretation TST interpretation depends on two factors: Diameter of the induration · Person's risk of being infected with TB and risk of progression to disease if infected · Mantoux is positive if induration is: 10mm in a well-nourished, HIV negative child 5mm in a malnourished, or HIV infected child · A negative mantoux does not rule out TB infection or disease (especially in the HIV positive or malnourished child)











)

 TB and DM preventive messages should be given in both care settings as patient education and CMEs to the facility staff.

- IPT is NOT recommended as a method of preventing TB in DM patients (studies have shown that there may not be any additional benefit to this and it may worsen peripheral neuropathy associated with DM).
- Improved collaborative activities would improve care and prevention of diabetes.
- Under-diagnosis of the disease is common, and could be improved by screening people with TB for diabetes.
- Management of diabetes must be optimized in general, and in particular during TB disease, as during all types of infections.





1. Setting up means of coordinating diabetes and TB activities

- TB/DM activities will ride on existing TB/HIV coordinating bodies that are already established.
- These will be established at national level, county, sub county and facility level.
- The purpose of the coordinating bodies will be to coordinate, strengthen and increase ownership of all TB/DM activities alongside TB/HIV activities.
- Additionally these teams will be tasked to address commodity issues, data quality issues, and to Identify and address any existing training gaps in different administrative levels.



Healthcare workers in the diabetes clinic will provide DOTs TB treatment
 as per the National guidelines

 Upon completion of TB treatment, patients with diabetes will be referred back to a specialist diabetes clinic for continued diabetes chronic care and management







TB in pregnancy

- In 2011, it was estimated that more than 200,000 cases of active tuberculosis occurred among pregnant women globally; the greatest burdens were in Africa and Southeast Asia.
- TB in pregnancy however, can present insidiously, since symptoms of malaise and fatigue may be attributed to pregnancy rather than disease, therefore during pregnancy it can be difficult to recognize weight loss
- Pregnant women with active TB disease should be treated as soon as the diagnosis of TB has been made with the standard 6 month regimen 2RHZE/4RH.
- · Anti-TBs are not dangerous in pregnancy and are compatible with breast feeding.
- Adherence to anti-TBs will cure tuberculosis, and prevent spreading tuberculosis to the unborn child as well as the household.
- Identification and treatment of maternal TB is the best way of preventing TB in the newborn.
- There is no significant increase in malformations for infants born to infected mothers and there is also **no indication for therapeutic abortion**



• If diagnosed among neonates, TB should be treated using the standard treatment regimens

TB prophylaxis among neonates and infants • Neonates born to mothers with active TB who screen negative for TB should be offered Isoniazid Preventive Therapy (IPT) prophylaxis

- BCG is then offered 2 weeks after completion of the 6 month course of IPT
- Though extremely rare, intrauterine transmission of TB may occur
- Once a baby is born to a mother with active TB disease, or an infant has close contact with active TB disease, evaluation of the newborn should be undertaken.







REPUBLIC OF KENY





Alcohol abuse among TB patients

 All TB patients must be asked about history of alcohol use to identify alcohol abusers

- Harmful drinking habits and or alcohol dependence could negatively impact TB treatment outcomes.
- Alcohol abuse should be recorded in the TB patient record card in order for the HCW to manage an abusive patients accordingly.

Management of alcohol abuse among TB patients Identify the risks and discuss the consequences of alcohol abuse Provide medical advice on the benefits and consequences of alcohol abuse Solicit patient commitment to reducing / stopping alcohol use Identify goals e.g. reduced drinking and eventual abstinence Give advice and encouragement to stop drinking Provide educational materials on alcohol cessation and abstinence.

 Screen for other co-morbidities particularly liver and kidney dysfunction









Management of Tobacco abuse among TB patients

- Discourage smoking by offering counseling and education on the dangers of smoking to themselves and others in their vicinity
- Explain that cessation will improve the patient's chances of getting cured; preventing TB related death and not spreading TB infection at home
- Positive benefits on smoking cessation should be highlighted such as saving money, gaining weight and health; protecting family members from the effects of second hand smoke and improved physical performance
- · Address any barriers they may have to guitting smoking
- A smoking cessation plan with set timelines should be drawn out together with the patient who is willing to quit smoking
- Assess the progress of the smoking cessation plan at every appointment and record this in the TB patient record card

-









- · This means the bacteria with resistant mutations are not killed
- Clinically manifested by disease progression despite treatment, failure to achieve negative sputum or cultures, and/or treatment



Health care provider factors	Drugs	Patients factors
Absence of guidelines Non compliance to guidelines Inadequate training Poor or no treatment monitoring	Inadequate supply Poor quality Poor storage conditions Wrong dose or combination Poor regulations of medicines	Poor adherence or poor DOT Lack of information Lack of transportation Adverse effects Social barriers
oorly organized or funded control programmes	•Unavailability of certain medicines	•Malabsorption






Classification of DR TB			
Monoresistance	Resistance to one first-line anti-TB drug only		
Polydrug resistance (PDR TB)	Resistance to more than one first-line anti-TB drug (other than both Isoniazid and Rifampicin)		
Rifampicin resistance (RR TB)	Resistance to Rifampicin detected using phenotypic or genotypic methods, with or without resistance to other Rif, Injectables or Quinolones. (i. RR TB without MDR TB) It includes any resistance to Rifampicin, whether monoresistance, multidrug resistance, Polydrug resistance or extensive drug resistance. (ii. AU RR TB forms)		
Multidrug resistance (MDR TB)	Resistance to at least both Isoniazid and Rifampicin		

Extensively drug Resistance to any Fluoroquinolone and to at least one of three second-line injectable drugs (Capreomycin, Kanamycin and Amikacin) in addition to multidrug	Pre-XDR :	Resistance to Isoniazid and Rifampicin and either a fluoroquinolone or a second-line
Extensively drug resistance (XDR TB)Resistance to any Fluoroquinolone and to at least one of three second-line injectable drugs (Capreomycin, Kanamycin and Amikacin) in addition to multidrug		injectable agent but not both.
TB) drugs (Capreomycin, Kanamycin and Amikacin) in addition to multidrug	Extensively drug resistance (XDR	Resistance to any Fluoroquinolone and to at least one of three second-line injectable
	ТВ)	Amikacin), in addition to multidrug



































*











Pattern of Drug Resistance	Regimen	Duration
Rifampicin Resistance	8 Km-Lfx-Cs-Pto-Z/12 Lfx- Cs-Pto-Z	20months
soniazid and Ethambutol and Pyrazinamide ± streptomycin	3 Km-Lfx-R-Z/15 LFX-R-Z	15 months
soniazid and Pyrazinamide	3 Km-Lfx-R-Z/15 LFX-R-Z	15 months
soniazid and Ethambutol	3 Km-Lfx-R-Z/15 LFX-R-Z	15 months
soniazid ± Streptomvcin	R/Z/E/Lfx	9 months





		treatment of KK-IB and	MDR-TB ^a
Group A. Fluoroquinolones ^b	Levof	oxacin	Lfx
	Moxif	loxacin	Mfx
	Gatifle	oxacin	Gfx
Group B. Second-line injectable agents	Amika	acin	Am
	Capre	omycin	Cm
	Kanar	nycin	Km
	(Strep	otomycin)°	(S)
Group C. Other core second-line agents ^b	Ethior	namide / prothionamide	Eto / Pto
	Cyclos	serine / terizidone	Cs / Trd
	Linezo	blid	Lzd
	Clofaz	zimine	Cfz
Group D. Add-on agents	D1	Pyrazinamide	Z
(not part of the core MDR-TB regimen)		Ethambutol	E
		High-dose isoniazid	Hh
	D2	Bedaquiline	Bdq
		Delamanid	Dim
	D3	p-aminosalicylic acid	PAS
		Imipenem-cilastatin ^d	Ipm
		Meropenem ^d	Mpm
		Amoxicillin-clavulanate ^d	Amx-Clv
		(Thioacetazone) ^e	(T)





Indications for Bedaquiline & Delamanid Pre-XDR and XDR TB patients In MDR TB, when group 4 drugs are compromised or severely toxic Severe intolerance to second line injectable Contraindications to any second line drugs Patient who have failed an MDR-TB regimen













		Treatment Outcomes	
MINISTRY OF HEALTH	Cured	DRTB patient who completes treatment with three or more consecutive negative cultures taken at least 30 days apart after the intensive phase.	
	Treatment completed	DRTB patient who has completed Treatment as recommended Without evidence of failure BUT no record that three or more Consecutive cultures taken at least 30 days apart are negative after the intensive phase.	
	Death	A patient who dies from any cause while on DR-TB treatment.	
	Loss to Follow Ups	A patient who interrupts DR-TB treatment for two or more consecutive months.	
	Treatment failure:	Treatment terminated or need for permanent regimen change of at least two anti-TB drugs because of:	
		Lack of conversion by end of the intensive phase; or	
		Bacteriological reversion in the continuation phase after conversion to negative	
		Evidence of additional acquired resistance to FQ or injectable drugs; or	
		Adverse drug reactions	
	Transfer out:	A patient who has been transferred to a reporting unit in another County and for whom the treatment outcome is unknown.	
	Not evaluated	A patient for whom no treatment outcome assigned. (This includes cases "transferred out" to another treatment unit and whose treatment outcome is unknown).	
	Treatment success	The sum of Cured and Treatment completed.	Same and



















· Do contact invitation/tracing

· Evaluate for active disease

-Physical examination

-Thorough history taking















Principles of DR TB treatment in children

- similar to adults.
- Empiric treatment using source regimen for DR-TB should be initiated promptly
- Drug dosages should be based on body weight
- · In culture-negative children with DR-TB. clinical criteria can be used to determine response to therapy and the duration of the intensive and continuation phases.
- Regimen ,DOTs plus and follow up is The DR-TB clinical teams should be involved in decisions made about paediatric cases.
 - The benefit of fluoroquinolone far outweighs the risk, and should be part of every DR-TB regimen.
 - Counsel the child's caregiver at every visit, to provide support, advice about adverse events and the importance of compliance and completion of treatment









- Start treatment of drug resistance in second trimester or sooner if condition of patient is severe.
 - The decision to postpone the start of treatment should be agreed by both patient and doctor after analysis of the risks and benefits
- Avoid injectable agents (Aminoglycosides -due to toxic effects to the developing foetal ear). Capreomycin has a lower risk of ototoxicity and is the drug of choice if an injectable agent cannot be avoided
- Avoid Eto&Pto and instead use PAS. Eto/Pto can increase the risk of nausea and vomiting associated with pregnancy, and teratogenic effects have been observed in animal studies.

* Pregnancy is not a contraindication to the treatment of MDR-TB



DR TB and Breastfeeding

- Infant formula should be substituted for breast milk because small quantities of the drugs will be passed into the milk
- Clinicians and parents should agree to breastfeeding when the formula is not a feasible option
- The mother and her baby should not be completely separated, the care of the infant should be left to family members if the mother is sputum smear positive until she becomes sputum smear negative
- The mother should be provided with an N-95 respirator if close infant – mother contact cannot be avoided or a surgical mask if no N-95 mask, until she converts

*Breastfeeding mothers should receive full course of DR TB treatment







τοχιζιτγ	ANTIRETROVIRAL AGENT	ANTITUBERCULOSIS AGENT
Peripheral neuropathy	D4T, ddl, ddC	Lzd, Cs, H, Amino glycosides, Eto∕Pto, E
Central nervous system (CNS) toxicity	EFV	Cs , H, Eto∕Pto, Fluoroquinolones
Nephrotoxicity	TDF	Aminoglycosides, Cm
Depression	EFV	Cs , Fluoroquinolones H, Eto∕Pto
Headache	AZT, EFV	Cs
Nausea and	RTV, D4T , NVP, and most others	Eto/Pto, PAS, H, E. Z and others





Drug	Frequency	Recommended dose and frequency for patients with Creatinine clearance < 30 ml/mir
-		or for patients receiving haemo-dialysis
Isoniazid	No change	300mg once daily or 900mg 3* wk.
Rifampicin	No change	600 mg once daily
Pyrazinamide	Yes	25-35 mg/kg/dose 3 * wk.
Ethambutol	Yes	15-25 mg/kg 3* wk.
Ofloxacin	Yes	600-800mg/dose 3 * wk.
Levofloxacin	Yes	750-1000mg/dose 3 * week
Moxifloxacin	No change	400mg once daily
Cycloserine	Yes	250mg OD or 500mg 3* wk.
Prothionamide	No change	15-20mg/kg/day
Para Aminosalicilic acid	No change	4g/dose twice daily
Capreomycin	Yes	12-15 mg/kg/dose 2 or 3 * wk.
Kanamycin	Yes	12-15 mg/kg/dose 2 or 3 * wk.
Amikacin	Yes	12-15 mg/kg/dose 2 or 3 * wk.
Clofazimine	No change	200-300mg daily











Management of adverse effects: Nausea and vomiting

• Suspected agents: PAS, Eto/Pto, Cs, Clofazimine, H, E, Z.

- Frequent during the first few weeks of therapy
- Usually cease with supportive therapy.
- Reversible upon discontinuation of the suspected agent.
- Reassure: encourage the patient to continue treatment.
- · Advise the patient to increase fluid intake.
- · Stagger the dose so patient does not have to take all drugs at once.
- The patient should take soft porridge before taking the doses.
- · Initiate anti-emetic therapy. Eg. Ondansetron.
- · Monitor Electrolytes and replenish if vomiting is severe.

Peripheral neuropathy

- S. Kn. AMK. CM. E. Pto
- · Patients with co-morbid disease such as diabetes or alcoholism are more likely to develop neuropathy (Not a contraindication to use of the above agents)
- Neuropathy generally not reversible upon discontinuation of anti-TB therapy
 - Only a small minority of patients requires long-term treatment to control symptoms
- Suspected agents: Cs, H, Lzd, FQ,
 Increase pyridoxine to max 200mg/ day in patients on second-line drug therapy, 50 mg/day for those on first-line therapy.
 - Initiate therapy with tricyclic antidepressants, carbamazepine, NSAIDS to alleviate severe symptoms
 - Physical therapy focusing on the affected regions may be of benefit.

Ototoxicity

Suspected agents; S, Km, Cm (rarely Pto/Eto)

- · Generally not reversible even on discontinuation of therapy.
- Audiometry for baseline and follow up testing is required
- Consider reducing the dose or dose frequency
- Change to Cm if patient is on Km



Psychosis

•Suspected agents: Cs, H, FQ, Pto

•Patients tend to present with hallucinations or delusions •The causes of psychotic symptoms in patients with DR TB may be related to socio-economic circumstances, underlying psychiatric disease

•Prior history of psychiatric disease is not a contraindication to the use of the above agents, though psychiatric side effects are more likely

·Some patients may need anti-psychotic medication throughout the duration of anti-TB therapy, though side effects are generally reversible upon discontinuation of treatment















Electrolyte loss

 Mild-to-moderate hypokalemia (i.e., 2.5 < K < 3.5 mEq/L, asymptomatic) and mild hypomagnesaemia (1.4 < Mg < 1.8 mg/dl, asymptomatic):

- Treated with oral supplements (40-80 mEq potassium chloride, 420-840 mg magnesium Sulphate)
- Repeat monitoring in 24-48 hours.
- Where it is not possible to measure magnesium:
 - If a patient has hypokalemia it should be assumed that he also has some degree of hypomagnesaemia

Potassium	Dose KCI in meq	Frequency of monitoring
level meq/L		(sooner if patient has vomiting/diarrhoea)
Above 3.6	None	Monthly
3.4-3.6	20-40	monthly
3.0-3.3	60	weekly
2.7-2.9	80	One to 2 days
2.4-2.6	80-120	daily
2.0-2.3	10meq/hr IV and 80 P.O every 6-24	Hourly after infusion until serum K* is > 2.8 meq/L
< 2	10 meg/hr IV and	Hourly after infusion until serum
	100 P.O every 6	K ⁺ is > 2.8 meq/L. Consider
	hours	withholding injectable until > 2.4











MODULE 4: LEPROSY

































Signs and symptoms of leprosy When to suspect leprosy Burning sensation in the skin Pale patches on the skin with loss of sensation Numbness and tingling the feet and/or hands Weakness of the eyelids, hands or feet Tender nerves Painless wounds or burns, swellings, especially on the face and ear lobes Large painless bumps on the skin that do not feel pain or heal for weeks or months

• Disappearance of eyebrows or eyelashes (madarosis)



MODULE 5: LABORATORY DIAGNOSIS OF TB AND LEPROSY








































































- · Slighting itching treat symptomatically with anti-histamine
- Anaemia Investigate for other causes of anaemia, refer to medical officer or DTLC for further management.
- Exfoliative darmatitis The skin is itchy, and letter peals off. Patient is very ill, stop drugs immediately and refer the patient to medical officer or DTLC or nearest hospital.
- Fixed drug reaction stop drugs. The eruption will slowly clear after stopping.















Complications of the eye

Red eye - It is an emergency; it is a serious sign in leprosy patient especially if combined with lagopthalmos. It needs carefully examination and often referral.

- · It may be caused by: -
- · Foreign body:

· - E.g. hair, insets, piece of grit etc; causing irritation and redness inspect and remove foreign body. Apply topical eye antibiotics and pad for 2 days.

Keratitis:

- · Inflammation of the cornea, caused by infection by bacteria or virus, often enhanced by drying out particularly in patients with logopthalmos
- · Treat with antibiotics topical and systemic, refer patient to eye specialist.

Complications of the eye

Acute Iridocyclitis

• Inflammation of iris and cilliary body, which is a result of type Il reaction in an MB Leprosy patient. It is characterized by:

- Acute red eye
- Loss of vision
- · Pin-point pupils not reacting to light
- · Photophobia
- Management Start patient on atropine eye ointment TDS and apply eye pad. Then refer patient immediately.

) Foot Problems among Leprosy Patients · Common problems are:- Plantar ulceration Foot drop · Fixed deformities of feet and toes · Tarsal disorganization. PLANTAR ULCERATION:--· Found in 10% of patients Manifestation of sensorimotor deficit Mostly in front part of sole in MTP joint Augmented by infection through fissures and paralysis of feet muscles(which counter the stress while walking)

Foot care in a leprosy patient

- Management:--1.
 - · Absolute bed rest and elevate foot
 - Soap soaking/ eusol bath, irrigation, dressing
 - · Remove slough or other draining procedures
- Start antibiotics
- · Protective foot wearing
- 2. Prevention:--

Protective footwear:-(type depends on state of foot)

 Feet with only sensory loss (no muscle paralysis), footwear should have tough outer sole, should not rub against toes. Eg using automobile tyre side pieces.











Deformity grading – EYES

- Grade 0: no eye problem due to leprosy; no evidence of visual loss.
- Grade 1: eye problems due to leprosy present, but vision not severely affected as a result of these (vision: 6/60 or better; can count fingers at 6 m).
- Grade 2: severe visual impairment (vision: worse than 6/60; inability to count fingers at 6 m) also includes lagophthalmos, iridocyclitis and corneal opacities.









MODULE 6: NUTRITION ASSESSMENT COUNSELLING AND SUPPORT





Definition of key terms **Objectives ***** By the end of this session, the participants will be able to:-Nutrition Define nutrition Nutrition refers to the sum of all processes involved in taking in of nutrients, their assimilation and use for proper body Define and categorize malnutrition functioning and maintenance of health. The successive Understand the effects of under-nutrition on body functioning stages include; ingestion, digestion, absorption, assimilation and excretion. Discuss the relationship and management nutrition in TB, Leprosy and Lung disease · It is also defined as the science of food and how it affects health and disease.









Food group	Recommended number of servings per day	One serving size is equal to either:- (1 cup = 250mls)	
Grains , bread and other starches	6 -11	1 silic of bread % cup of cooked riso/cereals % cup of y cereals % cup pats 1 boledroasted green banana A fist size of rout tubers (arrow roots, sweet potatoes, yams, casava) or % cup boled mashed Irish potatoes	
Vegetables	3 – 5	% cup vegetables cooked 1cup vegetables raw	
Fruits	2-4	1 cup fruit juice 1 medium piece fresh fruit	
Milk and milk products	2 - 3	1 cup skimmed/low milk 3/4 cup voghurt	
Meat and meat substitutes	2 - 3	57 – 87 cooked lean meat, poultry 28gms, 1 egg. cheese 26.5 gms,1/2 fish	
Fats and oils	Use sparingly	1 tea spoon margarine, salad dressing, peanut butter 1 table sooon	









are related to iron, vitamin A, and iodine.

for-age.
Micronutrient deficiencies are a result of reduced micronutrient intake and/or absorption. The most common forms of micronutrient deficiencies

The objectives of nutrition in Tuberculosis, leprosy and lung disease are;

- To prevent and correct malnutrition
- Reduce the effects of medication on patients
- To improve and maintain the nutritional status of patients
- Promote adherence
- To promote drug efficacy
- Restoring fat-free mass in chronic obstructive pulmonary disease.











…How TB affects Nutrition

- Due to the high fever, there is loss of body fluids sweating and urination during the acute phase. Electrolyte loss nitrogen break down
- Due to loss of appetite and anorexia during illness, there is reduced food intake and depletion of body stores.
- Mal-absorption due to the high metabolic rate leads to malnutrition and wasting.







- Diminished pharmacal-dynamic effectiveness of anti-mycobacterium drug regimen
- Impair the protective efficacy of Bacillus Calmette-Guerin (BCG)
- Delayed and prolonged wound healing
- Progressed disabilities



🕍 NACS

Nutrition assessment counseling and support (NACS) aims to establish routine nutrition assessment as an integral component of facility- and community-based health care providers to deliver nutrition-specific services. It links clients to nutrition-sensitive interventions provided by the health, agriculture, food security, social protection, education and rural development sectors.



***** Step I: Nutritional assessment Objectives** Obtaining, verifying and interpreting data in order to identify existing or potential problems By the end of this unit, the participants should be able to; • Judging a person's nutritional status, situation, and vulnerability to Define nutrition assessment poor nutrition by taking measurements and/or asking questions. • Explain the importance of nutritional assessment. • It leads to problem diagnosis and helps to design appropriate plan • Discuss the methods of nutrition assessment. of care or interventions. · Carry out accurate nutritional assessment. • It generates the information needed for a comprehensive approach to nutrition intervention · Be able to interpret nutritional assessment data · Based on results, patients can be referred for specialized care if/ when necessary.







Nutrition assessment methods

- Anthropometric measurements
- Biochemical assessments
- Clinical assessment (signs of deficiencies)
- Dietary (24 hour recall, food diary,)
- · Economic and social status
- Functional









Measuring height

- Make sure the measuring rod of the stadiometer is straight.
- Make sure the patient is barefoot.
- Ask the patient to stand with heels together, arms to the side, legs straight, shoulders relaxed. Heels, buttocks, scapulae (shoulder blades), and back of the head should be against the vertical board of the stadiometer.
- Just before the measurement is taken, ask the patient to inhale deeply, hold the breath, and keep an erect posture ("stand up tall") while you lower the headboard onto the highest point of the head with enough pressure to compress the hair.
- Read the measurement to the nearest 1 cm and keep your eye level with the headboard to avoid errors.









	Condition
≥30	Obese
25.0-29.9	Overweight
18.5–24.9	Normal BMI
16.0–18.5	Moderate acute malnutrition
<16.0	Severe acute malnutrition

//H level	Condition
80% or <-2Z Score	Moderate acute malnutrition without medical complications
70% or <-3Z Score	Severe acute malnutrition without medical complications
70% or <-3Z Score	Severe acute malnutrition with medical complications
'H level	Condition

















REPUBLIC OF KENYA			
MINISTRY OF HEALTH		Clinical assessn	nent
	Body part or system	Signs/Symptoms	Possible deficiency
	Hair	Lackluster, Thinness, sparseness, dryness, dyspigentation, easy pluckability, texture change	Proteins, protein-energy, Zinc, copper biotin.
	Face	Paleness, Moon face (swollen), Greasy scaling around nostrils (nasolabial)	Riboflavin, Niacin, Pyridoxine, Iron
	Eyes	Pale white eyes and eyelid lining (pale conjunctivae), Redness and fissuing of eyelid corners duliness and dryness (corneal or conjunctival xerosis), redness, lesions of conjunctivae (Bitot's spots)	Iron, folate, vitamin A, C, B2 $B_{\rm 0}$ and $B_{\rm 12}$
	Mouth	Angular redness, lesions or scars at the corners of the mouth (stomatilis), swelling and redness of lips and mouth (cheilosis)	Riboflavin Niacin pyridoxine iron
	Tongue	Smoothness, slickness (filiform papillary atrophy), beefiness, redness, pain (glossilis), swollen, magenta color	Niacin, pyridoxine, riboflavin, vitamin B_{12} folate, iron

Clinical a	assessment	
Body part or system	Signs/Symptoms	Possible deficiency
Gums	Swelling, sponginess, bleeding, receding	Vitamin C
Skin	Dryness, scaling, lightening of skin color often centrally on the face (diffuse pigentation), rough, gooseffesh skin (follicular hyperkeratosis), small skin hemorrhages (petechiae), excessive bruising, hyper pigented patches that may peel off, leaving superficial ulcers or hypo pigented skin (flaky paint dermatosis), odema, delayed wound healing.	Vitamin A, C and K, Zinc, essential fatty acids, proteín, Niacin.
Nails	Spoon-shape (kiolonychia), pale, brittle, ridged.	Iron
Glands	Enlarged thyroid or parotid	Protein, iodine
Musculoskeletal system	Bowlegs knock knees, enlarged joints, hemorrhages, muscle and fat wasting.	Protein-energy, Vitamin D and C, Calcium
Neurological system	Mental confusion, irritability, psychomotor changes, motor weakness, sensory loss	Thiamin, Riboflavin and Vitamin B12

ietary Assessmente Master title style Dietary history What to assess Obtaining a diet history involves -Total energy and nutrient intake interviewing the client on the past and/or current food -Macro- and micronutrient intake -Water and fluid intake practices -Eating habits Measuring/estimating adequacy -Drug and alcohol intake • of the food consumed (variety, -Food preparation methods amount, frequency, with whom, -Factors hindering food intake sources of food, preparation)







Objectives

By the end of this session participants should be able to

- Define nutrition diagnosis
- List the components of nutrition diagnosis
- Make a diagnosis using cut off points





Nutrition Diagnostic Statement (PES)

- A nutrition diagnostic statement is written in a PES format that states the Problem (P), the Etiology (E), and the Signs & Symptoms (S).
- Example of PES statement for a TB patient would be:
- Reduced food intake related to side effects of drugs as evidenced by weight loss and client reported history

Assessment diagnosis and classification of malnutrition in adults

ASSESS				
HISTORY	LOOK AND FEEL	CRITERIA	CLASSIFICATION	TREATMENT/CARE
Ask client or refer to records:	1. If client has oedema on both legs or base of the	Adults (non-pregnant and non-post-partum) BMI: < 16	SAM with complications (fever, hypothermia,	Inpatient treatment Follow Nutrition Care
 Has the client lost weight in the past month/since the last visit? 	spine, rule out pre- eclampsia, kidney problems, elephantiasis, heart failure, and wet beriberi (vitamin	if can't measure BMI, MUAC: < 19 cm OR Bilateral pitting oedema (both feet or legs are	severe anaemia or dehydration, vomiting, bilateral oedema +++) or no appetite	Plan for SAM in Inpatient care
 Has the client had: Active TB (on 	B1 deficiency with oedema)	swollen, and the skin remains indented when pressed with a finger)	SAM with appetite and no complications	Outpatient treatment
 treatment)? Another chronic OI or malignancy (e.g., 	 Measure client's weight (kg) and height (cm) 	Pregnant women and women up to 6 months post-partum	BMI: < 16 or MUAC: < 19 cm and no danger signs	Plan for SAM in Outpatient Care
oesophageal infections)?	3. Compute BMI	MUAC: < 21 cm or < 23 cm with weight loss		
– Mouth sores/oral thrush?	Weight (kg) Height (m ²)	Adults (non-pregnant and non-post-partum) BMI: > 16.0 to < 18.5	Moderate/mild malnutrition	Follow Nutrition Care Plan for MAM
3. Has the client's body composition/fat distribution	4 Measure MUAC for	MUAC: ≥ 19.0 to < 21.0 cm		
changed noticeably?	pregnant women, women	Pregnant women and women up to 6 months post-partum	Significant weight loss	
face?	partum, and adults who	Poor weight gain		
 Fat distribution on limbs, breasts, stomach, back? 	cannot stand straight	MUAC: ≥ 21 to < 23 cm		
	5. Examine for conditions that	Adults (non-pregnant and non-post-partum)	Normai	Pollow Nutrition Care
Has the client had:	cause secondary	BMI: ≥ 18.5 to 24.9		Nutritional Status
– Nausea and vomiting?	malnutrition	MUAC: ≥ 21.0 cm		
 Persistent fatigue? Poor appetite? 	6. Look for complications and danger signs (anaemia,	Pregnant and post-partum women (up to 6 months)		
	severe dehydration, active TB, severe bilateral	MUAC: ≥ 23 cm		

ASSESS				/
ASK	LOOK AND FEEL	CRITERIA	CLASSIFICATION	TREATMENT/CARE
Ask mother or caregiver	1. Look for severe visible	Bilateral pitting oedema (both	SAM	
or reter to records: 1. Has the child lost weight in the past	 Wasting: Loss of muscle bulk on arms, shoulders, 	teet and/or legs are swollen, and the skin remains indented when pressed with the thumb)	Bilateral oedema +++, marasmic kwashiorkor	Inpatient treatme Follow Nutrition
month/since the last visit?	buttocks, and thighs, with visible rib	OR	With no appetite or with medical complication (anorexia, intractable vomiting, convulsions, no	in Inpatient Care
 a. A cough for more than 21 days? (This 	 Sagging skin on buttocks 	6–59 months: < 11.5 cm 5–9 years: < 13.5 cm	alertness, lethargy, lower respiratory tract infection, high fever, severe anaemia or	
may be a result of	2. Check for oedema	10-14 years: < 16.0 cm	denydration, hypogiycaemia, hypothermia)	
HIV-related chronic	(swelling) in both feet	15–17 years: < 17.5 cm	With appetite and without medical complication	Outpatient
lung disease, such	3. Weigh the child	AND	Clinical wellness	treatment
as lymphocytic	4. Measure MUAC		Alertness Constitute able (willing be managed CAMA at home and	Follow Nutrition
interstitial	5. If MUAC measurement	Appetite test (pass or fail)	caregiver abley wining to manage SAW at nome and	Care Plan for SAM
pneumonia or	is not possible, then		Terum to clinic every 14 days	in Outpatient Care
bronchiectasis)	measure weight-for-	MUAC:	MAM	Follow Nutrition
treatment)?	shape of the curve on	6-59 months: ≥ 11.5 to < 12.5 cm		Care Plan for MAN
c. Diarrhoea (three or	the growth chart	5-9 years: ≥ 13.5 to < 14.5 cm	Poor weight gain	
more stools per	 Has the child lost 	10–14 years: ≥ 16.0 to < 18.5 cm		
days)?	weight since the last	15-17 years: ≥17.5 to < 19.5 cm		
d. Another chronic OI	visit? (Measure again	Weight gain parallel to or higher	Normal	Follow Nutrition
or malignancy?	to confirm current	than median growth curve		Care Plan for
	weight)		Growing appropriately	Normal Nutritiona
	 Is the growth curve 	MUAC:		Status
	flattening?	6-59 months: ≥ 12.5 cm		
	 Is the child gaining 	5-9 years: 2 14.5 cm		
	weight?	10-14 years. e 18.5 cm		

Changes in weight over time

Change of weight is also used as a measure of nutritional Issue and action in the TB clinic Unintentional decrease in weight >5% in 2–3 months Associated with increased risk of hospitalization -Dietary (and food security) assessment to ensure adequate intake: -Address infections -Nutritional counselling as necessary ≥10% in 2–3 months Associated with 5-fold or more risk of death compared with no weight change -Rehabilitation depending on BMI status, -Address infections -Address eating problems

Session 3: Nutrition interventions

Nutrition Intervention

An intervention is a specific set of activities and associated materials used to address the problem. Nutrition interventions are purposefully planned actions designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status for an individual, target group, or the community at large.









Provide the second s	What to consider Critical nutrition points (CNPs) Assist the TB patient at nutritional risk in achieving a positive change in food habits. Improve nutritional stanus and Prevent nutrition related problems through optimal use of the supplemental foods and other nutritious foods. Monthly assessments expecially weight. Increase food intake Sanitation, food hygiene and water safety. Positive living behaviors Physical activity. Drink safe, clean water 8 glasses a day. Manage food drug interactions. Provide micro nutrient supplement Follow-up and closely monitor the patient.
NUTRITION COUNSELING Should be patient-centered	Areas for counseling Weight management Drug reaction Adherence Dual infection increase or reduce intake Relapse Referral from community Rehabilitation

Nutrient	Normal (Kcals or grams)	Additional for TB patient	Food examples
	2100Kcal	300-500Kcals	1 to 2 cups of enriched porridge
	0.8 g/ Kg Bwt	0.4- 0.7g/kgBwt	Milk ,Egg, nuts, pulses and meat
	25 - 30% of total Kcals	Nil	Margarine, butter, vegetable oils,

Requirements Vitamins and minerals Vitamin A supplementation (every six months or as per the National Vitamin A supplementation schedule) and vitamin A rich foods. Patients on Isoniazid should ideally be supplemented with 25mg -50mg of pyridoxine B6 daily Other antioxidants Vitamin E, zinc and selenium neutralize free radicals and prevent the production of peroxides from lipids. Consider iron folic acid, supplementation depending on the haemoglobin level. Drink at least 8 glasses or more of clean and safe water per day Fiber Low fiber diet is recommended as the patient nutrient intake is impaired and they require high energy

Recommended energy and Protein Requirements for women during pregnancy and Lactation in TB

PREGNANCY				Extra energy for women
	Energy requirements		Protein requirements	with TB and of HIV
	Total nutrient requirements	36-40 kcal/kg/day	0.8-1.0g/kg/day	20-30%
	First trimester0-12 Wks	+150 kcal/day	+0.7g/kg	20-30%
	Second trimester 13-27 Wks	+300 Kcal/day	+3.3g/kg/day	20-30%
	3rt trimester 28-40 Wks	+300 kcal/day	5.8g/kg/day	20-30%
LACTATION				
	Total nutrient requirements +500 kcal/day		+20g/day	20-30%



Infant and Young Child Nutrition (IYCN) in the context of TB/HIV

- Breastfeeding is an unequalled way of providing ideal food for the healthy growth and development of infants.
- WHO recommends breastfeeding with appropriate use of anti-retroviral drugs for the mother and baby is the best option for overall well-being and survival of HIV exposed children.
- All HIV positive pregnant women shall be put on HAART for 12 weeks.
- However in special conditions replacement feeding may be considered if AFASS (Acceptable, Feasible, Affordable, Sustainable and Safe) criteria are met

Breastfeeding in Drug Resistance -TB

- A breastfeeding mother with DR-TB should receive a full course of anti-TB treatment, as timely and effective treatment is the best way to prevent transmission to her baby.
- The mother and her baby should not be completely separated. However, if the mother is sputum smear-positive, the cooperation of a family member should be sought to primarily care for the infant until the mother becomes sputum smear-negative.
- In cases where the mother has converted to smear negative the mother and infant may spend time together, in a well-ventilated area or outdoors.
- The mother should wear a surgical cloth mask during breastfeeding.
- Replacement feeding should only be considered in special conditions.



Recommendations

- Breastfeeding should be given on demand and mothers supported to exclusively breast feed for 6months with a continuation to 24months.
- Babies staying away from their mothers should be fed on Expressed breast milk .
- However, where this is not feasible due to drug toxicities or drugs effect on breast milk change in taste adequate information and support on replacement feeds should be provided





Feeding the Child Who is Ill

- Encourage the child to drink and to eat with lots of patience
- · Feed small amounts frequently
- · Give foods that the child likes
- Give a variety of nutrient-rich foods
- Continue to breastfeed often ill children breastfeed more frequently
- Vitamin A according to routine supplementation and disease target schedule







Nutrient Requirements for TB Patients

 Energy: chronic Tb patients are malnourished, energy needs are increased in order to minimize weight loss and achieve a desirable weight. An additional 300- 500 kcals (35 -40 kcals per ideal body weight) is recommended. This will help in protein sparing.

• *Protein* :An intake of 1.2- 1.5 g of protein per kg body weight is required to generate serum albumin levels per day, due to tissue wasting and repair of worn out tissues.



Nutrient requirements

- Fats/ oils: These should provide 25-30% or less of the total energy requirements of an individual.
- Minerals and vitamins: Reduced antioxidant intake (vitamins A, C, and E) causes a decrease in the body's immune response and also means that oxidant and free radical induced damage and inflammation increases.
- Vitamin A- supplementation of 200,000 IU is recommended during the intensive phase
- Patients on Isoniazid should ideally be supplemented with 25-50mg and up to 300mg in MDR of pyridoxine B6 daily
- Water: At least 8 glasses (each 250ml) or more of safe drinking water per day



		Moderate Acute Malnutrition
Eligibility	bilateral pitting Oedema + Weight for Height less than – 3 z score MUAC less than 11.5 cm Passed appetite test	Weight for Height less than – 2 MUAC between 11.5 – 12.5 cm
Prescription	 Nutrition counseling (care giver) Sachets of RUTF per Kg. Bwt per week Safe water solution 	Nutrition counseling (care giver) 100gms FBF per day Ready to use supplementary feeds(RUSF) 1 Satchet per day
Treatment follow Up	•weekly – seven days	•Monthly (30 days)
Discharge	Weight for height equal to – 1.0 Z score No oedema Passed appetite test	Weight for height equal to – 1.0 Z score

	Severe Acute Malnutrition	Moderate Acute Malnutrition
Eligibility	bilateral pitting Oederna + Weight for Height less than 3 z score MUAC less than 11.5 cm Passed appetite test	•Weight for Height less than – 2 z score •MUAC between 11.5 – 12 cm
Prescription	Nutrition counselling (care giver) 2. 21 – 35 sachets of RUTF per week	Nutrition counselling (care giver) 200gms FBF – per day or 3. 2 Satchets RUSF per day
Discharge	•weekly – seven days	•Monthly (30 days)

	Severe Acute Malnutrition	Moderate Acute Malnutrition
Eligibility	bilateral pitting oedema + BMI for Age less than – 3 Z score MUAC less than 13.5 cm Passed appetite test	•BMI for Age less than – 2 Z score •MUAC between 13.5 – 14.5 cm
Prescription	 Nutrition counselling 21 sachets of RUTF per week 100gm FBF per day 	 Nutrition counselling 200-300gms FBF – per day or 2 Sachets RUSF per day
Treatment follow Up	•weekly – seven days	Monthly (30 days)
Discharge	BMI for Age equal or greater than – 3.0 Z score No oedema for 10 days Passed appetite test	BMI for Age equal to or greater than – 1.0 Z score

	Severe Acute Malnutrition	Moderate Acute Malnutrition
Eligibility	bilateral pitting Oedema + BMI for Age less than – 3 Z score MUAC less than 16 cm Passed appetite test	•BMI for Age less than – 2 Z score •MUAC between 16 – 18.5 cm
Prescription	 Nutrition counselling 21 sachets of RUTF per week 200gms FBF per day 	 Nutrition counselling 200-300gms FBF – per month or 2 Sachets RUSF per day
Treatment follow Up	•weekly – seven days	•Monthly (30 days)
Discharge	BMI for Age equal or greater than – 3.0 Z score No Oedema for 10 days Passed appetite test	BMI for Age equal to or greater than – 1.0 Z score



	Severe Acute Malnutrition	Moderate Acute Malnutrition
Eligibility	Pitting Oedema + BMI less than 16 kg/m ² MUAC less than 16 cm MUAC 16 - 18.5 Passed appelite test	•BMI 18.5 kg/m ² •MUAC between 16 – 18.5 cm
Prescription	Nutrition counselling 21 sachets of RUTF per week 200gms FBF per day	Nutrition counselling 200-300gms FBF – per day or 3 2 Satchets RUSF per day
Treatment follow Up	•weekly (7 days)	•Monthly (30 days)
Discharge	•BMI equal to or greater than 16 kg/m ² •No Oedema for 10 days •Passed appetite test	BMI equal to or greater than 18.5 kg/m ²

	Severe Acute Malnutrition	Moderate Acute Malnutrition
Eligibility	Bilderal pitting Oredema + BMI less than 20 kg/m ² * MUAC less than 18cm Passed appetite test**	MUAC between 19 – 23 cm <u>Pregnancy</u> Observed low weight gain of < 1.3kg /month <u>Postpartum</u> Observed non intentional weight loss of > 0.7 kg/month and BMI < 20 kg/m ²
Prescription	Nutrition counselling 2. 21 sachets of RUTF per week 3. 200gms FBF per day	Nutrition counselling 2. 200-300gm FBF –per day
Treatment follow Up	•Weekly (7 days)	•Monthly (30 days)
Discharge	•MUAC equal to or greater than 19 cm •No Gedema for 10 days •Passed appetite test •Observed weight gain of above 1 kg/month during pregnancy •Steady weight gain after 6 weeks &BMI > or = 20 cm	MUAC = or > 23 cm

















Drug name	Food recommendation	Avoid	Possible side effects
Rifampicin	To be taken 1 hr before or 2 after food. 1 hr before antacids	alcohol	Nausea, vomiting, appetite loss
lsoniazid	Taken 1 hr before or 2 hrs after food. Give 10mg B_6 daily	Alcohol	Interferes with Hepatitis, Cutaneous hypersensitivity, Peripheral neuropathy
	May be taken with food	Avoid alcohol	Retrobulbar neuritis, Arthralgia
	Increase fluid intake		Taste changes, taste of food, nausea
	May be taken with food		Hepatitis, Nausea, Vomiting, Arthralgia
	Take with or after meals(Supplement with Vit B ₆)	Alcohol	Abdominal discomforts, nausea
	Take 2hrs before or after food	Antacids, milk products	Gastrointestinal reactions, Insomnia
	Can be taken without regard to food		Ototoxicity: hearing damage, vestibular, disturbance, Nephrotoxicity: deranged renal function test
	Increase fluid intake, take with foods high in potassium(bananas, avocados)		Ototoxicity: hearing damage, vestibular, disturbance, Nephrotoxicity: deranged renal function test
	Take with or immediately after food.	Alcohol	Gastrointestinal reactions Dizziness,
	Increase fluid intake		Headache, Depression, Memory loss
Cycloserine	Supplement with vitamin B ₆	alcohol	Dizziness, Headache, Depression,













- Encourage intake of lemon juice with honey which is a traditional remedy for coughs
- Provide foods which are rich in vitamin A as it is vital for healthy bronchial mucosa and helps relieve cough



- Provide antioxidants such as vitamins A, C and E as they enhance bronchial tubes' ability to withstand free radicals coming from environmental pollution
- Provide honey as it contains some pollen which can desensitize the body against environmental pollen
- Encourage consumption of onions. Onion is a bronchial dilator and antispasmodic which can relieve and prevent asthma attacks
- Reduce intake of food additives, salt, wine, beer and fish. Fish contains histamine which provokes all allergic reactions







- Unplanned weight loss from poor nutrition can further weaken the respiratory muscles
- Good nutrition helps prevent infections
- Poor nutrition can worsen COPD symptoms and decrease exercise tolerance

Role of nutrition in COPD cont:

• Patients should take a lot of water 6-8 glasses unless the clinician recommends otherwise. This helps to keep mucus thin, making it easier for body to cough it up. Some people find it easier to fill a container full of their daily fluid requirement in the morning and spread it out during the day.

Role of Nutrition in COPD cont: Decrease Sodium Intake

Reasons

- Eating too much salt causes fluid retention. Too much fluid can make breathing more difficult.
- To reduce sodium intake, patients should not add salt when cooking and should avoid the following
- Cured smoked and canned meats,
 - frankfurters, ham and salami
 Regular canned vegetables, soups and vegetable juices
 - Salted snacks (nuts, crisps)
 - Regular frozen meals

High sodium foods

- · Foods in brine (pickles, olives, Tuna)
- Regular processed cheeses
- Seasoned salt, meat tenderizer, MSG, soy sauce, barbeque sauce

Role of micronutrients in COPD

Calcium

 Calcium helps with lung function, muscle contraction and blood clotting. It works with

Magnesium

- Two cups of milk can satisfy the daily adult need for calcium.
- Sources of Magnesium include, dark green vegetables, whole grains, beans, peas, lentils, tofu and some seafood. Chocolate and cocoa contains some

Role of minerals in COPD Potassium • Required for muscle contractions. It is very important for the heart muscle. Foods high in potassium include: • Milk, yogurt, winter squash, tomatoes, apricots, cantaloupe,

potatoes, raisins, spinach and dates.

bananas, oranges, carrots,

Meal sizes and frequencies for patients with COPD Small more frequent meals i.e. 4 meals plus 2 snacks (6

- meals) that are energy dense help undernourished patients meet their caloric needs more efficiently.High fiber foods such as, vegetables, dried legumes, bran,
- whole grains, rice, cereals, pasta and fresh fruit aid in digestion by helping food move more easily through the digestive tract.



Meal sizes and frequencies for patients with COPD cont:

 Patients with COPD should not over eat as this makes breathing more difficult. Consuming carbonated beverages like Soda or carbonated water or gas-producing foods such as beans, cauliflower or cabbage can also cause bloating. Eliminating these types of beverages and foods will ultimately allow for easier breathing.




By the end of this session participants will

be able to

- Define pharmacovigilance, adverse drug reactions, and side effects
- Explain the rationale for Pharmacovigilance
- Discuss the roles and responsibilities of health care workers in pharmacovigilance
- Discuss the Guideline for the National Pharmacovigilance System in Kenya
- Discuss the tools for reporting in pharmacovigilance



Definition of Pharmacovigilance

"Pharmacovigilance is the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medicines, biological products, herbals and traditional medicines, with the view to:

- Identifying new information about hazards, and
 Preventing harm to patients."
- · Preventing narm to pa

From:

Greek pharmakon - drug

Latin vigilare - to keep awake or alert, to keep watch



What is a side effect?

• Any unintended effect of a pharmaceutical product occurring at doses normally used in humans, which is related to the pharmacological properties of the medicine







and Importance of PV

- Quality of medicines varies between companies in each country and between countries for the same product
- Distribution and use of medicines may vary (e.g. indications, dose, availability may all vary between countries)
- · Genetics, diet, traditions of the people also vary
- Pharmaceutical quality and composition (especially excipients) of locally and internationally produced pharmaceutical products may differ





























Hole of the Nurse

- Collect important ADR related information that a patient may not reveal to a doctor
- Inform clinicians of concerns in a patient's vital signs and laboratory reports

RELET OF THE Pharmacist

- Ensuring that medicines are used safely
- Prevention and early detection of suspected ADRs through involvement in patient care
- Review of treatment charts and medication counseling to alert patients of potential ADRs
- Collecting data on ADRs
- Educating other healthcare professionals about the prevention, detection and reporting of suspected ADRs.





wideline CROK CO Code State title style

- Introduction to ADRs and PV
- The proposed PV system in Kenya
- Reporting
- Flow of information
- Tools in PV

- ADR monitoring
- Roles and responsibilities
- Roll out and training
- Principles of efficient reporting
- Annexes and references

Tools

- Yellow form (PV I) Form for reporting suspected adverse drug reactions
- White card (PV 4)-Alert card
- Pink form (PV 6)- Form for reporting poor quality medicinal products







- errore curriculum errore erro
- Event: The event should contain information on signs, symptoms, disease, diagnosis, labs values, order of events, description of the event in patients own words, etc. Information on baseline characteristics including medical history, co-morbid conditions, etc., if available should also be reported.
- Product: Information on the product should include the generic name, brand name, strength, dosage, and batch number.
- Reporter: The reporter should provide their name, address, contact information, and relationship to the patient

MINISTRY OF HEALTH PV 4 PHARMACY AND POISONS BOARD LENANA ROAD, NAIROBI PO. BOX 27663 - 00506 TEL: (020) 2716905/6 Ext 114 Fax: (020)-2713431 / 2713409 ADVERSE DRUG REACTION ALERT CARD
PATIENT NAME:
AGE: GENDER:
DATE ISSUED: ADDRESS:
SUSPECTED DRUG(S):
DESCRIPTION OF REACTION:
Other comments (if any):
Tafadhali hakikisha umebeba kadi hii kila wakati. Kumbuka kumvonyesha mhudumu na afae kadi hii wana pata methabu.





harmacerigileneeiimKeeraitElexyef

What to report

- Suspected ADR
- Poor quality medicinal product

Who should report

- Patient
- Relatives
- Healthcare worker

When to report

- Fill the form as soon as possible on suspicion
- Send the form as soon as possible on completion

Where to send

- District pharmacist
- Designated official/organization
- PPB-department of pharmacovigilance

How to send

- Appointed courier
- Direct post
- Fax/Telephone/Email
- MoH system in existence







Case study I

ANM is a 32 year old male who comes to your facility complaining of dysphagia, cough, oral candidiasis and considerable weight loss. After several tests the patient is found to be eligible for ART and the clinical team decides to initiate him on d4T + 3TC + NVP and CTX for prophylaxis. 2 weeks later, patient prevents with SJS, diarrhea and excessive dehydration.

- Identify the problem in the above case
- Use the relevant tool (s) to enter and report the information

Case study 2

A consignment of Xmol (Paracetamol 120mg/5ml) is received at PPB dispensary in Koinange district on 10 June 2010 from KEMSA. The manufacturing date is 10 June 2009 and expiry date is June 2012. The batch number is X100 and the manufacturer is Koinange Pharma box 100 Koinange Kenya. 2 days after receiving it, you notice that the syrup appears to have glass like particles at the bottom and on comparing with the previous stock, the colour appears to be yellowish instead of pink. On examination, the product conforms with the labeling requirements

Case Study 2 (cont'd)

• Identify the problem in the above case

• Use the relevant tool (s) to enter and report the information

MODULE 7: NTLD-P COMMODITIES SUPPLY CHAIN MANAGEMENT PHARMACEUTICAL MANAGEMENT































Cont..

- Using and maintaining environmental controls
- Policy on the training and use of respiratory protection
- Area-specific infection control recommendations
- Description of roles and responsibilities for implementation and monitoring the infection control plan.
- Time-line and budget (e.g., material and personnel cos

Group Work

È

• You are the Facility In charge for Health facility X. You need to develop a plan :

- List and discuss the elements of the IPC plan
- Assuming you have a plan, how do you implement it?
- List and discuss the steps to implement it, including barriers and funding issues







































































Common disinfectants against MTB

- Chlorine based: Chlorine dioxide (Tristel, Jik) active against atypical MTB
- Aldehydes:

- Glutaraldehyde (2% for 20mins) for endoscopes
- Ortho-phthalaldehyde (OPA)
- Low-temperature steam formaldehyde sterilization
- Enzymatic disinfectants: For fibre-optics
- Peracetic Acid: applied instead of glutaraldehyde, but active against copper & brass
- Oxidative disinfectants: Hydrogen peroxide

Common disinfectants against MTB

- Phenol
- should be used at a concentration of 2% to 5% in water
- These compounds are used for the decontamination of surfaces (triclosan, chloroxylenol, orthophenylphenol are commonly used antiseptics).

Alcohols

 Alcohols, ethanol (denatured ethanol, methylated spirits) or iso-propanol, are used at 70%.

lodophors

- should be used at concentrations of 3% to 5
- · lodophors are useful for mopping up spills.









Room volume	Average air flowrate (Air volume x h)	ACH
4m x 4m x 2.5 m	m ³ x h	Flow/ volume
40 m ³	40	1
40 m ³	200	5
40 m ³	300	7.5
40 m ³	600	12

egrated Curriculum

airborne contaminants				
ACH	99%	99.9%		
2	138 min	207 min		
4	69	104		
6	46	69		
12	23	35		
15	18	28		
20	14	21		
50	6	8		
400	<1	1		











Personnel Protective Equipment: Masks



- Surgical masks reduce the spread of microorganisms from the wearer (protection from exhaled droplets)
- They do not provide protection to the wearer from inhaling small infectious aerosols


































































Quantification and Rational Quantification: This is the process of estimating the quantities of medicines and other commodities needed for a specific period of time in order to ensure an uninterrupted supply. Rationale: To ensure that there are sufficient quantities to meet clients' / patients' needs and avoid shortages/stock-outs. To avoid surpluses that may lead to over-stocking, expiries and/or wastage of commodities. To make informed procurement adjustments when faced with

grated Curri

• To make informed procurement adjustments when faced with budgetary constraints

Ø

Quantification methods used in TB commodities

Consumption method

The consumption based method uses historical data on the actual medicines dispensed to patients to calculate the quantity of medicines that will be needed in the future.

Morbidity method

The morbidity-based method uses data about diseases and the frequency of their occurrence in the population (incidence or prevalence) or the frequency of their presentation for treatment.

















		Но	w t	o I	Rec	eiv	ve						
RY OF HEALTH													
	Bin	Card											
	FOR 85	M			RE	PUBLIC	OF KE	NYA					
						BIN CA	RD						
	ITEM	CODE NO.			UNIT OF ISS	UE .			SERIAL N	UMBER			
	ITEM	DESCRIPTION			STORAGE RI	QUIREM	ENTS		LEDGER C	ARD N	o.		
									LOCATION	•			
		Issue /						Issue /					
	• •	Voucher No.	t	Issue	e	*	Date	Voucher No.	t	•	e	6	
		B/F From Card No.	8/F										
						-	<u> </u>						
					-	-	<u> </u>		-				-
		C/F											15.
													-









Storage: conditions, Temperature Store Commodities at Manufacturer's recommended conditions. Have Air conditioner if possible Should have the Max-Min thermometers Always follow the manufacturers instructions when storing commodities.



















Good Record keeping	Stock keepin	ig records
Records to track stock levels and transactions:	Level of Use	Inventory Record
Inventory records	Receiving and storing commodities	Delivery Notes Bin cards/stock ledge
Other records:	Issuing	Bin cards S11/S12
Temperature Log: To monitor temperature	Dispensing	Daily activity registers AL register and Tally sheets
	Reporting & Ordering	SORF , Health facility monthly summaries





MODULE 8: ENGAGING COMMUNITIES, PATIENTS AND NON STATE ACTORS (NSA) IN TB, LEPROSY AND LUNG HEALTH CARE SERVICES

















 A effective system of supervision and monitoring of community volunteers /CHEWs





Integrated Curricul				
REPUBLIC OF KENYA	Tasks and respo	nsibilities	Non state actors	
RESERVOR REALEY	Treatment supporters - Give patients daily supervised treatment Ensurer regular replenishment of drugs - Ensure the medicines are stored in a dry and cool place - Assist with case finding and detection through referral - Transport sputum specimens to health facility and collect results from facility - Recognition of adverse effects and referral - Transport effertal - Transport effertal - Transport effertal - Transport potum - Provide psychosocial support.	 TB coordinators Train health facility staff on identifying, supervising, and training treatment supporters Monitor progress of community care Support training and supervision of peripheral health care workers in engaging with community groups. Support and facilitate training, coordination, and supervision of community health volunteers/workers. Network with CSOs and other stakeholders 	 Educate the communities on TB, leprosy and Asthma. Mobilise the communities Mobilise resources Support implementation of lung health control activities Document community-based best practices. Undertake research and impact assessment. Facilitate case finding for presumptive TB, leprosy and asthma clients Support patients to access diagnostic services Purporte treatment adherence Promote provision of social and livelihood support for patients Promote patients' rights and responsibilities. 	













- Develop and display posters and other IEC materials that feature natural ventilation and cough hygiene.
- Train CHWs and TB treatment and adherence supporters on TB infection control and how to conduct home visits.
- Educate household members on TB infection control measures.
- Emphasize TB signs and symptoms, adherence to treatment and cough etiquette.



MODULE 9: ADVOCACY AND COMMUNICATION

REPURIE OF REALTH	
ADVOCACY AND COMMUNICATION	



Objectives

By end of this session the participant will be able

- 1. To define advocacy and communication (A&C)
- 2. To explain the objectives and targets of each approach
- 3. To describe how A&C activities support TB, Leprosy and Lung disease control objectives
- 4. To plan and respond to an issue through advocacy

What is Advocacy?

Advocacy is a broad set of coordinated efforts designed to:

- Place TB, Leprosy and other Lung Diseases higher on the political agenda.
- Strengthen government commitment to implement or improve TB, Leprosy and other Lung Diseases control policies.
- · Increase and sustain financial and other resources.



Ad	lvocacy	
<u>Changes</u> :	Policies, programs, funding, political commitment, media coverage.	
Targets:	Decision-makers, community leaders, people with influence, media.	
<u>Activities/App</u>	proaches: Lobbying, Partnership meetings, Parliamentary debates, Political events, Official memoranda, Petitions & Letter/Email campaigns, engaging champions, peaceful street processions, policy briets, media	
Successes:	Formulation/revision of relevant policies, better programs, more funding, more discussion of TB, Leprosy and other Lung Diseases among politicians, positive coverage of TB, Leprosy and other Lung Diseases in media.	

KEY ADVOCACY AREAS FOR NTLD-P

- Raise the profile of TB, leprosy and lung diseases through targeted public and private stakeholders and TB ambassadors/champions in order to influence relevant policy changes.
- Increase the visibility of TB messages to raise awareness and debunk myths and misconceptions regarding TB, MDR-TB and XDR-TB. These will be done through health-related events, such as World TB day, World Malaria Day, World Diabetes Day, Day of the African Child, Day for the Elderly, and Reproductive Health Day.
- Increase resource allocation to address TB, leprosy and lung diseases

KEY ADVOCACY AREAS FOR NTLD-P

- Promote screening for TB and lung diseases to increase diagnosis and access to care and treatment.
- Normalize TB and by so doing reduce stigma associated with TB by promoting TB ambassadors, celebrity spokespersons, testimonials and public discourse on TB, Leprosy and Asthma
- Increase disclosure of current and past TB and Leprosy patients to increase treatment adherence and reduce stigma























Communication

Cha	es: knowledge, allitudes, benaviors.	
<u>Targ</u>	 patients, providers, communities, policymakers, opinion leaders, service providers, nongovernmental organizations. 	
<u>Activ</u>	ies: use of information, education and communication materials (e.g. Brochures, posters), Media campaigns, Special events, health counseling, Trainings, presentations, Brand logos, promotional giveaways	
Suce lea cor	sses:improved knowledge and/or attitudes that o a new or different behavior (positive for TB ol	

























MODULE 10: MONITORING AND EVALUATION















PUBLIC OF KENYA	Purpose of Monitoring	
SIRT OF HEREIN	• To check that activities are implemented, measure progress towards objectives, identify problems as they come up, identify strengths that can be built on, and adapt to changing circumstances.	
	• The overall purpose is to identify strengths and weaknesses in a program, and provide the people responsible for program-planning and decision making with sufficient information <i>to make the right decisions</i> at the right time to improve its quality.	
	Informs day to day management of interventions	

PUBLIC OF KENYA	Domains	s of Monitoring	
	Domain	Definition	
	Input	Resources going into conducting and carrying out the program activities.	
	Process	Set of activities in which program resources (human and financial) are used to achieve the results expected from the program	
	Outputs	Immediate results obtained by the program through the execution of activities e.g. number of TB patients started on treatment	
	Outcome	An intermediate change obtained by the program through the execution of activities e.g. improved treatment success rate	and the second se
	Impact	Long-term and lasting significant changes following an intervention e.g. reduced TB burden in Kenya	×.







	Definition of	Terms used in Evaluation
MINESTRY OF HEALTH	Term	Definition
	Efficiency	A measure of how economically resources/inputs (funds, expertise, time etc.) are used to achieve results in a project or program.
	Effectiveness	The extent to which an intervention has attains its major relevant objectives in a project or program
	Relevance	the extent to which the objectives, outputs, or outcomes of an intervention are consistent with beneficiaries' requirements, Program policies, country needs, and/or global priorities.
	Sustainability	The degree to which services or processes continue once inputs (funding, materials, training, etc.) provided by the original source(s) decreases or discontinues.



Monitoring vs. Evaluation



Monitoring vs. Evaluation

Monitoring

- Determines sufficiency and appropriateness of current capacity to do the job on hand
- Informs day-to-day management
- Formative

Evaluation

- Assesses implications for the stakeholders
- Assesses technical soundness and appropriateness of strategy
- Can be formative or summative

















Components of a functional M&E System

- Should have a well defined M&E plan.
- · Have clear data sources

- Human and financial resources
- Clearly defined roles and responsibilities at all levels
- DQA and technical assistance mechanisms should be in place
- Working partnerships for planning, coordination and management e.g. TB/HIV collaboration
- · Data demand and use
- Surveys and Surveillance





















ratea cumculu	im					
LIC OF KENYA	Core TE					
MINESTRY OF HEALTH	Indicator definition		Source of data	Frequency	Level	
	Treatment Success Rate (bacteriologically confirmed.)	Numerator: number of bacteriologically confirmed cured and treatment completed among those started on treatment. Denominator: Total number of bacteriologically confirmed cases notified.	Facility TB treatment register and Patient records cards TIBU Cohort report.	Quarterly.	Facility Sub,county County and National.	
	Treatment Success Rate (all forms)	Numerator Number of TB cases (all forms) who successfully completed treatment Denominator. Total number of TB cases (all forms) who were notified.	Facility TB treatment register and Patient records cards TIBU Cohort report	Quarterly.	Facility Sub,county County and National.	
	Number of TB cases (all forms) notified to the national program	Number of TB cases (all forms) notified to the national program	TB register TIBU	Quarterly	Facility Sub county County and National	
	Number of Bacteriologically confirmed TB cases	Number of Bacteriologically confirmed TB cases that were notified.	TB register TIBU	Quarterly	Facility Sub county County National	

REPUBLIC OF KENYA	TB/HIV				
HERESTRY OF HEALTH	Indicator definition	Description (include Numerator and denominators)	Source of data	Frequen cy	Level
	Number and Percentage of TB patient tested for HIV with known results	Numerator: Number of TB patient tested for HIV with known results Denominator: Total Number of TB patients all forms notified.	T B register TIBU	Quarterly	Facility Sub county County National
	TB/ HIV Co-infection rate	Numerator: Number of TB patient with HIV positive results. Denominator: Total number of TB all forms tested for HIV.	T B register TIBU	Quarterly	Facility Sub county County A n d National
	Percentage of TB patient who tested HIV positive and initiated on ART.	Numerator: Number of TB patient who tested HIV positive and have been put on ART Denominator: Number of TB patient who tested HIV positive	T B register TIBU	Quarterly	Facility Sub county County National
	Proportion of children under 5 who are contacts of TB patients put on IPT	Numerator: Number of children under 5 exposed to smear positive TB	Contact and IPT	Quarterly	Facility Sub county

grated Curriculum				
REPUBLIC OF KENYA DR TB				
Indicator definition	Description (include Numerator and denominators)	Source of data	Frequency	Level
Number of laboratory confirmed DR-TB patients enrolled in second line anti-TB treatment	Number of DR TB cases notified	D R T B registers TIBU	Quarterly	Facility Sub county County National
Percentage of eligible TB patients receiving Drug Susceptibility Testing (M ol e c u l a r an d conventional) for DR TB among the people eligible for Drug Susceptibility Testing according to national policy.	Numerator: Number of cases done DST. Denominator: Number of Cases eligible for DST.	TB Registers Lab Records LIMS	Quarterly	Facility Sub county County National
Treatment Success Rate	Numerator: Number of DR TB cases who got cured or completed treatment	D R T B	Quarterly	Facility Sub county

REPUBLIC OF KENYA	Nutrition				
MINESTRY OF HEALTH	Indicator definition	Description (include Numerator and denominators)	Source of data	Frequency	Level
	Percentage of patients on treatment with BMI recorded in the treatment register	Numerator: Number of patients on treatment with recorded BMI in the treatment register. Denominator: Number of patients (all forms) on treatment.	TIBU TB registers	Quarterly	Facility Sub county County National
	Percentage of patients with BMI under 18.5 on nutrition support	Numerator: Number of patients with BMI under 18.5 on nutrition support. Denominator: Total Number of patients with BMI under 18.5.	TIBU TB registers	Quarterly	Facility Sub county County National

Integrated Curriculu	im						
REPUBLIC OF KENYA	Lepro	sy					
MINISTRY OF HEALTH	Indicator definition	Description (include Numerator and denominators)	Source of data		Level		
	Treatment success rate	Numerator: Number of patients in a given treatment cohort that completed treatment Denominator: Total number of patients started on treatment in a given cohort	L e p r o s y Register TIBU	Quarterly	Facility, Sub c National	ounty, County,	
	Number of leprosy cases notified (by grade)	Number of leprosy cases notified (by grade).	L e p r o s y register	Quarterly	Facility, Sub c National	ounty, County,	
	Number of health workers trained on Leprosy control.	Number of health workers trained on Leprosy control.	Training Database at the National Level.	Quarterly	Facility, Sub c National	ounty, County,	
	Number of Skin Screening Clinics held	Number of Skin Screening Clinics held	S T L C Quarterly report	Quarterly	Facility, Sub c National	ounty, County,	
	proportion of MB cases among new cases	Numerator: Number of MB cases among new cases Denominator: Number of new leprosy cases put on treatment	L e p r o s y Register TIBU	Quarterly	Facility, Sub co National	ounty, County,	
	proportion of household contact cases among new cases	Numerator: Number of household contact cases among new cases Denominator: Number of new leprosy cases put on treatment	L e p r o s y Register TIBU	Quarterly	Facility, Sub co National	ounty, County,	

REPUBLIC OF KENYA	PAL				
	Indicator definition		Source of data		
	Number of patients screened for Asthma	This indicator provides an absolute number of patients screened for Asthma in a particular month	Asthma register/ OPD Register	Monthly	Facility
	Number of new Asthma Cases put on treatment				Facility, Sub county, County, National
	Asthma treatment success rate	Numerator: Number of asthma cases put on treatment one year prior and with improved or stable treatment outcome Denominator: Total number of asthma patients put on treatment one year prior	Asthma Register	Quarterl y	Facility, Sub county, County, National

grated Curriculum					
REPUBLIC OF KENYA	Laborato	ory			
KENESTRY OF HEALTH	dicator definition	Description (include Numerator and denominators)	Source of data	Frequenc y	Level
Pro per Ext (E mic	oportion of laboratories erforming quarterly sternal Quality Assurance E Q A) for smear icroscopy	Numerator: Number of laboratories performing quarterly External Quality Assurance (EQA) for smear microscopy. Denominator: Total Number of laboratories performing smear microscopy.	EQA Reports	Quarterly	Sub county County National
Per sh per of t tho for du	ercentage of laboratories h owing a dequate erformance(concordance '95% and above) among ose that received EQA or smear microscopy uring the reporting period	Numerator: Number of laboratories showing adequate performance (concordance of 95% and above). Denominator: Number of laboratories performing quarterly External Quality Assurance (EQA) for smear microscopy.	EQA Reports	Quarterly	Sub county County National

Integrated Curriculu	m					
REPUBLIC OF KENYA	GeneXpe	rt				
MENESTRY OF HEALTH	Indicator definition	Description (include Numerator and denominators)	Source of data	Frequenc y	Level	
	GeneXpert utilization rate	Numerator: Number of GeneXpert tests done in the period under review Denominator: Number of expected GeneXpert tests in the review period.	GeneXpert Register and GX Alert System.	Quarterly	Facilities with GeneXpert machines. County National	
	GeneXpert Error Rate	Numerator:				

Integrated Curriculu	im					
REPUBLIC OF KENYA	IPC					
MINESTRY OF HEALTH	Indicator definition	Description (include Numerator and	Source of data	Frequenc v	Level	
		denominators)				
	Number of health	Number of health	Training Database at the	Quarterly	Facility Sub-county	
	on TB Infection	on TB Infection	National Level		County	
	Prevention	Prevention			National	
	Control(IPC)	Control(IPC)				
	Number of TB IPC	Number of TB IPC	Training	Quarterly	Facility	
	team members trained	team members trained	Database at the		Sub county	
	on IPC	on IPC	National Level		County National	
	Number of Health Care	Number of Health Care	Facility Based	Bi-	Facility	(Day)
	Workers (HCWs)	Workers (HCWs)	Reports	Annually	Sub county	
	sensitized on facility	sensitized on facility		during TA	County	

EPUBLIC OF KENYA	Commur	iity				
NESTRY OF HEALTH	Indicator definition	Description (include Numerator and denominators)	Source of data	Freque ncy	Level	
	Number and Percentage of patients referred by CHVs	Numerator: Number of patients(all forms) referred by CHVs Denominator: Number of patients (all forms) put on treatment.	TB Register TIBU	Quarter ly	Facility Sub county County National	
	Number and percentage of Patients on DOTs by CHV	Numerator: Number of patients(all forms) on DOTS by CHVs Denominator: Number of patients	TB Register TIBU	Quarter ly	Facility Sub county County National	Ø



No	Name of Tool	Purpose	Location	Filled By
1	Patient Record Card	The card is filled by health worker and acts patient clinical record card.	TB Clinic	Clinicians
2	Patient Appointment Card(ITB,IPT, DRTB, Leprosy and Asthma)	The card is used for scheduling TB appointment and acts as a reminder to patient	Patient	Clinicians
3	Facility TB Register	It is a TB Case listing which summarizes key variables for tracking TB patient progress and outcomes	TB Clinic	Clinicians
4	Sputum/GeneXpert	Used by clinicians to request for sputum / GeneXpert tests	TB Clinic	Clinicians to request and lab personnel to fill results
5	AFB Register	It is a case listing for all AFB microscopy tests done in the lab.	Lab	Lab personnel
6	Patient referral form from TB clinic.	Used for referring patients for management of other conditions than TB	TB clinic.	Clinicians.
7	Patient referral form to TB clinic	Used for referring presumptive TB cases from HIV clinic and other service delivery points to TB clinic	Other service delivery points outside TB clinic	Clinicians

No	Name of Tool	Purpose	Location	Filled B
IPT				
8	Intensive Case Finding /IPT Card – Adults -	This form is used both for screening of adult HIV patients for TB and recording IPT information for eligible patients	TB and HIV clinics.	Clinicians
9	Intensive Case Finding/IPT – Peds	This form is used both for screening of children for TB and recording IPT information for eligible children	TB and HIV clinic	Clinicians
10	IPT Register	It is a Case listing which summarizes key variables for tracking IPT patient progress and outcomes	TB and HIV clinic	Clinicians
DR T	в			
12	Culture/DST Log Book	To capture patients whose samples have been sent for culture and DST and results	TB clinic	Clinicians
13	Culture request form	Used to request for culture/DST for DR TB surveillance	TB Clinic	Clinicians
14	DR TB Patient Log Book	Individual patient management booklet that records all information regarding the patient.	TB clinic	Clinicians
15	DR TB Register	DRTB Case listing which summarizes key variables for tracking patient progress and outcomes	TB clinic	Clinicians
16	DR TB Patient Appointment Card	The card is used for scheduling IPT appointment and acts as a reminder to patient	Patient	Clinicians
17	DR TB baseline and follow up test request	Baseline and follow-up request form for DR TB patient.	TB clinic	Clinicians

Integrated Curriculum

Ν	Name of	Purpose	Location	Filled
0	Tool			Ву
CO	MMODITY TOOLS			
18	Facility Daily Activity Drug Register	To monitor the use of the TB and DR-TB drugs on a daily basis	TB clinic/ Pharmacy	Clinician/ Pharmacist
19	FCDRR	It's a reporting tool for consumption of TB, and DR TB drugs	TB clinic/ Pharmacy	Pharmacist/ clinician
20	Bin Card	This card is used to monitor stock of commodities in facility store or pharmacy	Pharmacy/Store	Pharmacist
21	S11	This form is in triplicate and is used to issue out commodities to various service delivery points within the facility	Pharmacy/Store	Pharmacist
22	PV Reporting Tools	To record and report all Adverse Drug Reactions experienced by patients on anti TB drugs	TB Clinic	Clinicians
Com	munity TB			
23	Community Monthly Reporting Tool	Reporting tool for community TB	Facility	CHV
24	Community Treatment Interrupters tracing form	used to track patient who have defaulted TB treatment.	Community	CHV
25	Community TB Screening Form	It is an ICF cards Used for screening TB in the community	Community	CHV.
26	Community Referral Form	Used to refer presumptive TB cases, contact tracing and treatment interrupters from community to the facility (edingues), and treatment	Community	CHV.

Commodities and Community TB Tools N Name of Purpose Locatio Filled o Tool n By LEPROSY 28 Leprosy appointment card The card is used for scheduling leprosy appointment and acts as a reminder to patient Patient Clinician The card is filled by health worker and acts as patient clinical record card 29 Leprosy record card TB Clinic Clinician 30 It is a leprosy case listing which summarizes key variables for tracking TB patient progress and outco eprosy registe PAL 31 Asthma Register It is Asthma Case listing register which summarizes key variables for tracking Asthma patient progress The card is filed by health worker and acts as patient clinical record card used for clinical notes during treatment Outpatient/Chest Clinic Clinician 32 JOB AIDS/ SOPs Monthly Data Cha It's a monthly summary chart that shows facility performance in various indicators TB Clinic 34 Data/Information flow chart This is a chart that provides clinicians with info on how information flows from facility TB Clinic --20



tod Curriculum












Exercise 1	(cont)	
Dimension of data quality	Definition	
5. Confidentiality	e. System used to generate data protected from deliberate bias or manipulation for political or personal reasons.	
6.Precision	 f. Data correct, with minimal errors i.e no bias 	
7. Timeliness	g. Clients are assured that their data will be maintained according to national and/or international standards for data.	



Dimensions of data quality

Definitions

- Accuracy Data correct, with minimal errors i.e no bias
- Validity.Ensuring the same fields are used consistenly for the same information captured.
- Completeness: Data appropriately inclusive as per the information system
- Timeliness: Data up to date (current) and information available in time









246 Integrated Curriculum Participants Manua















































Characteristics of a Good Research Question

• PECO

- Patient / population: who are the relevant patients / population?
- Exposure: What are the exposures (or the strategies) we want to compare?
- Comparison: Is there a group without the exposure or strategy to compare to?
- Outcome: What are the consequences that we wish to study?













MODULE 11: SOCIAL PROTECTION, POVERTY ALLEVIATION AND ACTIONS ON OTHER DETERMINANTS OF TUBERCULOSIS









BOAL End the global tuberculosis epidem: NDICATORS MLESTURE TARGETS 2020 2025 SDG 2030 END TB 2035 Reduction in number of T8 deaths monared with 2015 [%] 35% 75% 90% 95% Reduction in T8 incidence rate monared with 2015 [%] 20% 50% 80% 90% 90% Reduction in T8 incidence rate statistophic costs (46 to 18 (%) 24r0 (<25/100 cost) (<26/100 cost) 2/ero Zero Zero
MILESTONES TARGETS 2020 2025 SDG 2030 END TB 2035 seduction in number of TB deaths 35% 75% 90% 95% seduction in Bundhene rate 20% 50% 80% 95% deduction in Bundhene rate 20% 50% 80% 90% seduction in Bundhene rate 20% 50% 80% 90% Basterophic costs due to TB (%) 2ero Zero Zero Zero Zero PRINCIPLES Extended Sector Extended Sector Extended Sector Extended Sector Extended Sector
NDICATORS 2020 2025 SDG 2030 END TB 2035 Reduction in number of TB deaths 35% 75% 90% 95% mapared with 2015 (%) 35% 75% 90% 95% teduction in TB incidence rate 20% 50% 80% 90% mapared with 2015 (%) (<45/100 000) (<15/100 000) (<10/100 000) (<10/100 000) Ta-affected families facing Zero Zero Zero Zero Zero PRINCIPLES
RINCIPLES 35% 75% 90% 95% Verticities 20% 50% 80% 90% 90% Index of the deaths 20% 50% 80% 90
Reduction in 78 incidence rate 20% 50% 80% 90% compared with 2015 (%) (<85/100 000)
TB-affected families facing Zero Zero Zero ztastrophic costs due to TB (%) Zero Zero Zero
PRINCIPLES



















NESTRY OF HEALTH			
	Indicator	Recommended Target	
	TB treatment coverage ≥ 90%	TB treatment coverage ≥ 90%	
	TB treatment success rate ≥ 90%	TB treatment success rate ≥ 90%	
	$\%$ TB-affected households that experience catastrophic costs due to TB $_{0\%}$	% TB-affected households that experience catastrophic costs due to TB $$0%$$	
	% Newly notified TB patients diagnosed with WHO-recommended rapid tests $\ \ge 90\%$	% Newly notified TB patients diagnosed with WHO-recommended rapid tests $\gtrsim 90\%$	
	LTBI treatment coverage ≥ 90%	LTBI treatment coverage ≥ 90%	
	Contact investigation coverage ≥ 90%	Contact investigation coverage ≥ 90%	-
	DST coverage of TB patients ≥ 100%	DST coverage of TB patients ≥ 100%	(che
	Documentation of HIV status among TB patients ≥ 90%	Documentation of HIV status among TB patients ≥ 90%	
	Case fatality ratio ≤ 5%	Case fatality ratio ≤ 5%	-







The cycle of TB and poverty 2/2

- · Even when TB services are free of charge, the disease is costly to the poor.
- The average TB patient loses three to four months of work time and up to 30% of their yearly household earnings.
- · Families may be forced to sell what little livestock or land they have to access diagnosis
- The poverty cycle worsens as children are forced to quit school as there is no money for uniforms or fees, or because they have to work to support the family.
- · In this manner, poverty is passed on from generation to generation.



CHALLENGES AND BARRIERS THAT HINDER

- ECOTOMIC Safriers There is a complex pathway to care
- · Geographical barriers distance from services providing TB diagnosis and treatment
- · Socio-cultural barriers stigma and lack of knowledge of TB and available TB services
- · Health system barriers lack of health system

OVERCOMMING BARRIERS TO TB Kenya s Constitution 2010, Chapter 4 under the Bill of Rights, Article 43 guarantees fundamental social and economic rights to its people. These include; 43: 1 (a) to the highest attainable standard of health, which includes the right to health care services, including reproductive health care; 43:1 (c) to be free from hunger, and to have adequate food of acceptable quality;

43:1 (e) to social security; and

43: (3) The State shall provide appropriate social security to persons who are unable to support themselves and their dependants.

Superior Control of Control































